Author: "M Zdravkovic" / Topic: business - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"M Zdravkovic"' showing total 33 results

Start Over Author "M Zdravkovic" Topic business

33 results on '"M Zdravkovic"'

1. Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea

Author: Lidija Memon, Ana Ninic, B. Šupljeglav, V. Radisavljević, V. Gardijan, Miron Sopić, Vesna Spasojevic-Kalimanovska, Marija Mihajlovic, Jelena Munjas, M. Zdravkovic, and A. Milojević
Subjects: medicine.medical_specialty, biology, business.industry, CD36, medicine.disease, Peripheral blood mononuclear cell, Obstructive sleep apnea, Endocrinology, Internal medicine, Gene expression, biology.protein, Medicine, In patient, Resistin, Cardiology and Cardiovascular Medicine, business
Published: 2020
Full Text: View/download PDF

2. Management of dyslipidaemia in patients with coronary heart disease : results from the ESC-EORP EUROASPIRE V survey in 27 countries

Author: Guy De Backer, Piotr Jankowski, Kornelia Kotseva, Erkin Mirrakhimov, Željko Reiner, Lars Rydén, Lale Tokgözoğlu, David Wood, Dirk De Bacquer, G. De Backer, P. Jankowski, K. Kotseva, E. Mirrakhimov, Z. Reiner, L. Rydén, L. Tokgözoğlu, D. Wood, D. De Bacquer, A. Abreu, C. Aguiar, J. Badariene, J. Bruthans, A. Castro Conde, R. Cifkova, J. Crowley, K. Davletov, D. De Smedt, J. De Sutter, J.W. Deckers, M. Dilic, M. Dolzhenko, H. Druais, V. Dzerve, A. Erglis, Z. Fras, D. Gaita, N. Gotcheva, D.E. Grobbee, V. Gyberg, H. Hasan Ali, P. Heuschmann, A.W. Hoes, N. Lalic, S. Lehto, D. Lovic, A.P. Maggioni, S. Mancas, P. Marques-Vidal, L. Mellbin, D. Miličić, R. Oganov, N. Pogosova, Ž. Reiner, M. Stagmo, S. Störk, J. Sundvall, K. Tsioufis, D. Vulic, D.A. Wood, C. Jennings, A. Adamska, S. Adamska, J. Tuomilehto, O. Schnell, E. Fiorucci, M. Glemot, F. Larras, V. Missiamenou, A. Maggioni, C. Taylor, T. Ferreira, K. Lemaitre, L. Raman, D. DeSmedt, A.M. Willems, M. De Pauw, P. Vervaet, J. Bollen, E. Dekimpe, N. Mommen, G. Van Genechten, P. Dendale, C.A. Bouvier, P. Chenu, D. Huyberechts, A. Persu, A. Begic, A. Durak Nalbantic, A. Dzubur, N. Hadzibegic, A. Iglica, S. Kapidjic, A. Osmanagic Bico, N. Resic, N. Sabanovic Bajramovic, F. Zvizdic, T. Kovacevic-Preradovic, S. Popovic-Pejicic, D. Djekic, T. Gnjatic, T. Knezevic, Lj Kos, B. Stanetic, G. Topic, Borislav Georgiev, A. Terziev, G. Vladimirov, A. Angelov, B. Kanazirev, S. Nikolaeva, D. Tonkova, M. Vetkova, D. Milicic, A. Bosnic, M. Dubravcic, M. Glavina, M. Mance, S. Pavasovic, J. Samardzic, T. Batinic, K. Crljenko, D. Delic-Brkljacic, K. Dula, K. Golubic, I. Klobucar, K. Kordic, N. Kos, M. Nedic, D. Olujic, V. Sedinic, T. Blazevic, A. Pasalic, M. Percic, J. Sikic, R. Cífková, K. Hašplová, P. Šulc, P. Wohlfahrt, O. Mayer, M. Cvíčela, J. Filipovský, J. Gelžinský, M. Hronová, H. Hasan-Ali, S. Bakery, E. Mosad, H.B. Hamed, A. Ibrahim, M.A. Elsharef, E.F. Kholef, A. Shehata, M. Youssef, E. Elhefny, H. Farid, T.M. Moustafa, M.S. Sobieh, H. Kabil, A. Abdelmordy, E. Kiljander, P. Kiljander, H. Koukkunen, J. Mustonen, C. Cremer, S. Frantz, A. Haupt, U. Hofmann, K. Ludwig, H. Melnyk, M. Noutsias, W. Karmann, R. Prondzinsky, C. Herdeg, T. Hövelborn, A. Daaboul, T. Geisler, T. Keller, D. Sauerbrunn, M. Walz-Ayed, G. Ertl, R. Leyh, T. Ehlert, B. Klocke, J. Krapp, T. Ludwig, J. Käs, C. Starke, K. Ungethüm, M. Wagner, S. Wiedmann, P. Tolis, G. Vogiatzi, E. Sanidas, K. Tsakalis, J. Kanakakis, A. Koutsoukis, K. Vasileiadis, J. Zarifis, C. Karvounis, I. Gibson, A. Houlihan, C. Kelly, M. O'Donnell, M. Bennati, F. Cosmi, B. Mariottoni, M. Morganti, A. Cherubini, A. Di Lenarda, D. Radini, F. Ramani, M.G. Francese, M.M. Gulizia, D. Pericone, K. Aigerim, B. Zholdin, B. Amirov, B. Assembekov, E. Chernokurova, F. Ibragimova, A. Kodasbayev, A. Markova, A. Asanbaev, U. Toktomamatov, M. Tursunbaev, U. Zakirov, S. Abilova, R. Arapova, E. Bektasheva, J. Esenbekova, K. Neronova, K. Baigaziev, G. Baitova, T. Zheenbekov, T. Andrejeva, I. Bajare, G. Kucika, A. Labuce, L. Putane, M. Stabulniece, E. Klavins, I. Sime, L. Gedvilaite, D. Pečiuraite, V. Sileikienė, E. Skiauteryte, S. Solovjova, R. Sidabraite, K. Briedis, I. Ceponiene, M. Jurenas, J. Kersulis, G. Martinkute, A. Vaitiekiene, K. Vasiljevaite, R. Veisaite, J. Plisienė, V. Šiurkaitė, Ž. Vaičiulis, D. Czarnecka, P. Kozieł, P. Podolec, J. Nessler, P. Gomuła, E. Mirek-Bryniarska, P. Bogacki, A. Wiśniewski, A. Pająk, R. Wolfshaut-Wolak, J. Bućko, K. Kamiński, M. Łapińska, M. Paniczko, A. Raczkowski, E. Sawicka, Z. Stachurska, M. Szpakowicz, W. Musiał, S. Dobrzycki, J. Bychowski, D.A. Kosior, A. Krzykwa, M. Setny, A. Rak, Z. Gąsior, M. Haberka, K. Szostak-Janiak, M. Finik, J. Liszka, A. Botelho, M. Cachulo, J. Sousa, A. Pais, A. Durazzo, D. Matos, R. Gouveia, G. Rodrigues, C. Strong, R. Guerreiro, J. Aguiar, M. Cruz, P. Daniel, L. Morais, R. Moreira, S. Rosa, I. Rodrigues, M. Selas, A. Apostu, O. Cosor, L. Gaita, L. Giurgiu, C. Hudrea, D. Maximov, B. Moldovan, S. Mosteoru, R. Pleava, M. Ionescu, I. Parepa, A. Arutyunov, A. Ausheva, S. Isakova, A. Karpova, A. Salbieva, O. Sokolova, A. Vasilevsky, Y. Pozdnyakov, O. Antropova, L. Borisova, I. Osipova, M. Aleksic, B. Crnokrak, J. Djokic, S. Hinic, T. Vukasin, M. Zdravkovic, N.M. Lalic, A. Jotic, K. Lalic, L. Lukic, T. Milicic, M. Macesic, J. Stanarcic Gajovic, M. Stoiljkovic, D. Djordjevic, S. Kostic, I. Tasic, A. Vukovic, B. Jug, A. Juhant, A. Krt, U. Kugonjič, D. Chipayo Gonzales, J.J. Gómez Barrado, Z. Kounka, G. Marcos Gómez, M.V. Mogollón Jiménez, C. Ortiz Cortés, P. Perez Espejo, Y. Porras Ramos, R. Colman, J. Delgado, E. Otero, A. Pérez, M.R. Fernández-Olmo, J. Torres-LLergo, C. Vasco, E. Barreñada, J. Botas, R. Campuzano, Y. González, M. Rodrigo, C. de Pablo, E. Velasco, S. Hernández, C. Lozano, P. González, A. Castro, R. Dalmau, D. Hernández, F.J. Irazusta, A. Vélez, C. Vindel, J.J. Gómez-Doblas, V. García Ruíz, L. Gómez, M Gómez García, M. Jiménez-Navarro, A. Molina Ramos, D. Marzal, G. Martínez, R. Lavado, A. Vidal, V. Boström-Nilsson, B. Kjellström, B. Shahim, S. Smetana, O. Hansen, E. Stensgaard-Nake, A.J. Klijn, T.J.P. Mangus, R.J.G. Peters, W. Scholte op Reimer, M. Snaterse, S. Aydoğdu, null Ç Erol, S. Otürk, C. Tulunay Kaya, Y. Ahmetoğlu, O. Ergene, B. Akdeniz, D. Çırgamış, S. Akkoyun H Kültürsay, M. Kayıkçıoğlu, A.B. Çatakoğlu, A. Çengel, A.A. Koçak, M.A. Ağırbaşlı, G. Açıksarı, M.E. Çekin, E.B. Kaya, D. Koçyiğit, Z. Öngen, E. Özmen, V. Sansoy, A. Kaya, V. Oktay, A. Temizhan, S. Ünal, null İ Yakut, A.K. Kalkan, E. Bozkurt, H.A. Kasapkara, C. Faradzh, L. Hrubyak, L. Konoplianyk, N. Kozhuharyova, L. Lobach, V. Nesukai, O. Nudchenko, T. Simagina, L. Yakovenko, V. Azarenko, V. Potabashny, A. Bazylevych, M. Bazylevych, K. Kaminska, L. Panchenko, O. Shershnyova, T. Ovrakh, S. Serik, T. Kolesnik, H. Kosova, A. Hoye P Atkin, D. Fellowes, S. Lindsay, C. Atkinson, C. Kranilla, M. Vinod, Y. Beerachee, C. Bennett, M. Broome, A. Bwalya, Lindsay Caygill, L. Dinning, A. Gillespie, R. Goodfellow, J. Guy, T. Idress, C. Mills, C. Morgan, N. Oustance, N. Singh, M. Yare, J.M. Jagoda, H. Bowyer, V. Christenssen, A. Groves, A. Jan, A. Riaz, M. Gill, T.A. Sewell, D. Gorog, M. Baker, P. De Sousa, T. Mazenenga, J. Porter, F. Haines, T. Peachey, J. Taaffe, K. Wells, D.P. Ripley, H. Forward, H. McKie, S.L. Pick, H.E. Thomas, P.D. Batin, D. Exley, T. Rank, J. Wright, A. Kardos, S.-B. Sutherland, L. Wren, P. Leeson, D. Barker, B. Moreby, J. Sawyer, J. Stirrup, M. Brunton, A. Brodison, J. Craig, S. Peters, R. Kaprielian, A. Bucaj, K. Mahay, M. Oblak, C. Gale, M. Pye, Y. McGill, H. Redfearn, M. Fearnley, Cardiology, ACS - Atherosclerosis & ischemic syndromes, Graduate School, ACS - Heart failure & arrhythmias, Ege Üniversitesi, and Erasmus MC other
Subjects: 0301 basic medicine, Male, medicine.medical_specialty, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences, Dyslipidaemia, Coronary Disease, 030204 cardiovascular system & hematology, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, LDL-Cholesterol, Diabetes mellitus, Hospital discharge, Medicine, Humans, In patient, EUROASPIRE, Coronary heart disease, Lipid lowering therapy, Secondary prevention, Aged, Dyslipidemias, Coronary event, business.industry, Medical record, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti, Anticholesteremic Agents, Cholesterol, LDL, Middle Aged, medicine.disease, Optimal management, Europe, 030104 developmental biology, Health Care Surveys, Emergency medicine, Female, Guideline Adherence, business, Cardiology and Cardiovascular Medicine
Abstract: WOS: 000468732700018, PubMed ID: 31054483, Background and aims: One of the objectives of the ESC-EORP EUROASPIRE V survey is to determine how well European guidelines on the management of dyslipidaemias are implemented in coronary patients. Methods: Standardized methods were used by trained technicians to collect information on 7824 patients from 130 centers in 27 countries, from the medical records and at a visit at least 6 months after hospitalization for a coronary event. All lipid measurements were performed in one central laboratory. Patients were divided into three groups: on high-intensity LDL-C-lowering-drug therapy (LLT), on low or moderate-intensity LLT and on no LLT. Results: At the time of the visit, almost half of the patients were on a high-intensity LLT. Between hospital discharge and the visit, LLT had been reduced in intensity or interrupted in 20.8% of the patients and had been started or increased in intensity in 11.7%. In those who had interrupted LLT or had reduced the intensity, intolerance to LLT and the advice of their physician were reported as the reason why in 15.8 and 36.8% of the cases, respectively. LDL-C control was better in those on a high-intensity LLT compared to those on low or moderate intensity LLT. LDL-C control was better in men than women and in patients with self-reported diabetes. Conclusions: The results of the EUROASPIRE V survey show that most coronary patients have a less than optimal management of LDL-C. More professional strategies are needed, aiming at lifestyle changes and LLT adapted to the need of the individual patient., ESC - EORP; AmgenAmgen; Eli LillyEli Lilly; PfizerPfizer; SanofiSanofi-Aventis; Ferrer; Novo NordiskNovo Nordisk, The EUROASPIRE V survey was carried out under the auspices of the ESC - EORP. Since the start of EORP, the following companies have supported the programme: Amgen, Eli Lilly, Pfizer, Sanofi, Ferrer and Novo Nordisk. The sponsors of the EUROASPIRE surveys had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript.
Published: 2019

3. AB1059 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL´S DISEASE

Author: F De Benedetti, A. Thatayatikom, M. Wikén, H. Andersson, E. Rabinovich, S. Ohlman, Laura E. Schanberg, S. Cederholm, M. Zdravkovic, Peter A. Nigrovic, N. Singh, R. Schneider, A. Taxter, A. Cooper, Jonathan S. Hausmann, S. Akoghlanian, and W. Winn Chatham
Subjects: medicine.medical_specialty, Anakinra, business.industry, Immunology, Placebo-controlled study, Arthritis, Placebo, medicine.disease, Rash, General Biochemistry, Genetics and Molecular Biology, Discontinuation, Rheumatology, Internal medicine, medicine, Immunology and Allergy, medicine.symptom, business, Serositis, Progressive disease, medicine.drug
Abstract: Background:Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare autoinflammatory disorders associated with an activated IL-1 pathway, characterized by spiking fever, rash, arthritis, lymphadenopathy, hepatosplenomegaly and serositis. There is a growing understanding that SJIA and AOSD are one disease with different ages of onset, i.e. Still’s disease. The anaSTILLs study (anakinra inStill´sdisease) was designed to further evaluate efficacy and safety of anakinra in patients with Still´s disease across all age groups.Objectives:The primary objective was to demonstrate efficacy of anakinra versus placebo as assessed by ACR30 response with absence of fever at Week 2. Secondary objectives included: early onset of efficacy, sustained efficacy, time to study drug discontinuation, safety, pharmacokinetics, clinical signs and biomarkers.Methods:‘anaSTILLs’ was a randomized, double-blind, placebo-controlled, 12-week study including patients with active and newly diagnosed (6 months) Still´s disease according to adapted ILAR criteria if Results:12 patients were randomized and received study drug: 6 anakinra (2 mg/kg n=2, 4 mg/kg n=4) and 6 placebo, the study was terminated early due to slow recruitment. 1 patient on placebo had lymphoma, not Still’s disease, and was excluded; thus in total 11 patients were analyzed for efficacy, 8 were children [median (range) age=4.0 (1-11) years] and 3 were adults [median (range) age=32.0 (25-51) years]. 55% were male and the mean symptom duration was 74.2 days. All patients on anakinra but none on placebo achieved ACR30 response with absence of fever at Week 2 (p-value=0.0022). The efficacy of anakinra was further demonstrated by superiority to placebo in ACR50/70/90 responses with absence of fever at Week 2. All placebo patients discontinued the study within 6 weeks, 2 due to progressive disease, 2 due to lack of efficacy and 1 due to withdrawal by patient. There was a numerically higher proportion with early onset of efficacy (Week 1) in the anakinra group compared to placebo. The ACR30/50/70/90 responses in the anakinra group were sustained throughout the study period. Patients in the anakinra group had a prompt and persistent decrease in CRP and ferritin levels at Week 1, which was not observed in the placebo group. There were no unexpected safety findings. All anakinra patients developed anti-drug antibodies (ADAs) at some timepoint during the study. ADAs were persistent throughout the treatment period, except in one patient. Titers were low to moderate. One placebo patient had low ADA titers at one occasion. No neutralizing antibodies were observed and the ADAs did not appear to impact clinical efficacy or safety.Conclusion:Anakinra is superior to placebo in the treatment of Still’s disease. ADAs occur frequently but do not appear to adversely impact efficacy or safety. These results confirm the benefits of anakinra treatment in patients with active, newly diagnosed Still´s disease across ages.Disclosure of Interests:Laura Schanberg Grant/research support from: Sobi, BMS, Consultant of: Aurinia, UCB, Sanofi, Peter Nigrovic Grant/research support from: Novartis, BMS, Pfizer, Consultant of: Novartis, BMS, Pfizer, Sobi, Miach Orthopedics, Simcere, XBiotech, Quench Bio, Ashley Cooper: None declared, Winn Chatham Grant/research support from: Sobi, Consultant of: Sobi, Shoghik Akoghlanian: None declared, Namrata Singh: None declared, Egla Rabinovich Grant/research support from: AbbVie, UCB Pharma, Janssen Research & Development, Akaluck Thatayatikom: None declared, Alysha Taxter: None declared, Jonathan Hausmann Consultant of: Novartis, Milan Zdravkovic Shareholder of: Sobi, Employee of: Sobi, Sven Ohlman Shareholder of: Sobi, Employee of: Former employee of Sobi, Henrik Andersson Employee of: Sobi, Susanna Cederholm Shareholder of: Sobi, Employee of: Sobi, Margareta Wikén Shareholder of: Sobi, Employee of: Former employee of Sobi, Rayfel Schneider Grant/research support from: Roche, Novartis, Sobi, Pfizer, Consultant of: Sobi, Novartis, Novimmune, Fabrizio De Benedetti Grant/research support from: AbbVie, Pfizer, Novartis, Novimmune, Sobi, Sanofi, Roche, Speakers bureau: AbbVie, Novartis, Roche, Sobi
Published: 2020
Full Text: View/download PDF

4. AB0595 Antiphospholipid syndrome (HUGHES SYNDROME) is a disease with protean faces: multidisciplinary approaches on serbian cohort of aps patients

Author: A. Djokovic, N. Stanisavljevic, G. Bogdanovic, Ljudmila Stojanovich, and M Zdravkovic
Subjects: medicine.medical_specialty, Systemic lupus erythematosus, business.industry, medicine.disease, Thrombosis, Epilepsy, Antiphospholipid syndrome, Internal medicine, Cohort, medicine, Endocarditis, medicine.symptom, business, Stroke, Livedo reticularis
Abstract: Background Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombophilic state and circulating antiphospholipid antibodies (aPL) including anti beta2-GPI. Objectives Since than it became one of the most systemic conditions. In the last three and half decades, a variety of clinical manifestations involving almost all organs and tissues (cardiac, pulmonary, neurological, renal, cutaneous, hematologic, gastrointestinal, ocular, skeletal and endocrinology), have been described associated with antiphospholipid antibodies (aPL). Methods Our study comprises a total of 608 patients: 420 primary APS (PAPS) patients and 188 SLE patients with secondary APS (SAPS). aPL analysis included detection of aCL, as2GPI, and LA. Results Thrombosis was diagnosed in 46.5% patients, with higher prevalence in PAPS compared to SAPS patients: 51.2% and 38.3%, respectively, p=0.045. Pseudoinfective endocarditis was observed in 12.8% secondary APS patients and 3.1% in primary APS patients (p=0.004). 30% of the patients with high levels of aCL IgG antibodies had valve thickening and dysfunction, as compared to 4.1% without valve abnormalities (p=0.002). Presence of s2GPI IgG was significantly related to stroke, and overall s2GPI (IgG and IgM) positivity was significantly related to TIA in SAPS patients. Valvular manifestations were significantly related to TIA in both groups of patients and were independent risk factors for TIA in PAPS (OR 3.790 CI 1.597–8.998 p=0.003: table 2). In PAPS, epilepsy correlated with s2GPI-IgM, migraine with aCL-IgM, thrombocytopenia with aCL-IgM, aCL-IgG, anti s2GPI-IgG and LA. Livedo reticularis was more prominent in PAPS with high levels of aCL-IgG. Skin ulcerations were more prevalent in aCL-IgM positive SAPS patients and epilepsy more frequently had high levels of anti s2GPI-IgG in SAPS. Conclusions In this cross-section analysis of a large cohort of APS patients we analysed that APS patients can be presented with a wide variety of thrombotic and nonthrombotic manifestations. The key the success is multidisciplinary approach in all time of patient’s life. Antiphospholipid syndrome is really a disease with protean faces. References [1] Hughes GR. The antiphospholipid syndrome: ten years on. Lancet1993; 342:341–4. [2] Ardalan MR, Vahedi A. Antiphospholipid syndrome: A disease of protean face. J Nephropathology 2013; 2(1):81–4. [3] . Stojanovich L, Markovic O, Marisavljevic D, at all. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National cohort study. Lupus 2011; 0: 1–8. [4] Stojanovich L, Kontic M, Djokovic A, et al. Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study. Clin Exp Rheumatol. 2013; 31(2):234–42. Acknowledgements Acknowledgement: Funding: This work was supported by research grant number 175041, and TR 32040 for 2011–2018, issued by the Ministry of Science of the Republic of Serbia. Disclosure of Interest None declared
Published: 2018
Full Text: View/download PDF

5. Romantic Love as a Threat to Social Stability in Shakespeare’s 'Romeo and Juliet' and Anouilh’s 'Romeo and Jeanette'

Author: Jovana M. Zdravkovic and Milena M. Kalicanin
Subjects: Literature, business.industry, media_common.quotation_subject, Tragedy, romeo and juliet, subversion, shakespeare, P1-1091, Art, Romance, romantic love, lcsh:Philology. Linguistics, lcsh:P1-1091, Argument, Affection, romeo and jeannette, Subversion, business, transgression, Philology. Linguistics, media_common, anouilh
Abstract: In this paper we focus on the comparative analysis between Shakespeare’s Romeo and Juliet and its modern version, Anouilh’s Romeo and Jeannette . Anouilh is a representative of modern playwrights who evoke Shakespeare in their argument that a number of structures in our society are enemies of the authentic individual. What they adopt from Shakespeare is the capacity of man to relate with the world in a loving way. We argue that Anouilh’s Romeo and Jeannette fits the template of Shakespeare’s Tragic Equation – the mythical pattern present in all of the Bard’s works, the tragedy of the Lover devoid of love. These works evoke Shakespeare’s warning: that modern society is not conducive of love. On the contrary, the system is based on the suppression of genuine human affection; its re-emergence would subvert the dominant power-relations. In the introduction, we attempt to define the notion of romantic love by referring to the works of Bloom, Illouz, Vyvyan, etc. The following two segments of the paper deal with the analysis of the romantic relationship in Shakespeare’s Romeo and Juliet and its modern evocations in the work of Anouilh. In the conclusion, the destructive tendencies of the (modern) patriarchal society are yet again highlighted and linked to Shakespeare’s warning and desire to make his audience and readers perceive, judge and finally condemn them.
Published: 2018

6. EARLY ELECTROCARDIOGRAM CHANGES IN HIGHLY TRAINED PREADOLESCENT FOOTBALL PLAYERS

Author: S. Mazic, D. Zdravkovic, Goran Koracevic, Ivan Soldatovic, Sergej Prijic, V. Vukomanovic, Branislav Filipović, Vukan Cupic, Mirjana Krotin, Ivana Nedeljkovic, Branislav Milovanovic, P. Stevanovic, M. Zdravkovic, S. Dimkovic, T. Acimovic, and Olivera Markovic
Subjects: Body surface area, medicine.medical_specialty, Football players, biology, business.industry, Athletes, Left atrium, Reference range, Football, biology.organism_classification, QT interval, medicine.anatomical_structure, Internal medicine, Internal Medicine, Cardiology, Medicine, cardiovascular diseases, Cardiology and Cardiovascular Medicine, business, Wall thickness
Abstract: objective. To assess the early electrocardiogram (ECG) changes induced by physical training in preadolescent professional football players. design and methods. Ninety-four highly trained male football players (mean age — 12,85 ± 0,84 years) competing in the Serbian Football League (at least 7 training hours/week) and 47 age-matched healthy male controls were enrolled in the study. They were screened by ECG and echocardiography at a tertiary referral cardiocentre. The control group had sedentary life style (less than 2 training hours/week). Characteristic ECG intervals and ECG voltage were compared and reference range was given for preadolescent footballers. results. Highly significant differences between preadolescent athletes and sedentary controls were registered in all ECG parameters: P wave voltage (p 0,05). QTc interval duration in athletes was not very strongly, but indeed positively correlated with left atrium dilatation, left ventricular (LV) end-systolic and end-diastolic dimensions, LV myocardial index (LVMI), LVM/body surface area (BSA) 1,5 and LVM/h 2,7 indices. There was no correlation between QTc interval duration and LVM as well as LV wall thickness. conclusions.
Published: 2015
Full Text: View/download PDF

7. FRI0689 Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome (APS) patients

Author: M Zdravkovic, N. Stanisavljevic, Ljudmila Stojanovich, and A. Djokovic
Subjects: 030203 arthritis & rheumatology, medicine.medical_specialty, biology, business.industry, Autoantibody, Paraoxonase, 030204 cardiovascular system & hematology, medicine.disease, medicine.disease_cause, PON1, Gastroenterology, Thrombosis, 03 medical and health sciences, 0302 clinical medicine, Antiphospholipid syndrome, Internal medicine, medicine, biology.protein, Platelet, Endothelial dysfunction, business, Oxidative stress
Abstract: Background APS pathophysiology is not clear enough yet since it has been implicated that aPL can activate cells (endothelial cells, monocytes, platelets), interfere with hemostatic reactions and activate complement reactions [1,2]. Objectives The aim of this study was to evaluate oxidative stress markers and it relations to endothelial damage as risk factor for thrombosis in patients with primary (PAPS) and secondary (SAPS) antiphospholipid syndrome (APS) in correlation to traditional risk factors. Methods Flow mediated (FMD) and nitroglycerine (NMD) induced dilation of the brachial artery were studied in 140 APS patients (90 PAPS, 50 SAPS) and 40 controls matched by age, sex and conventional risk factors for atherosclerosis. Markers of oxidative stress: lipid hydroperoxydes (LOOH), advanced oxidation protein products (AOPP), total sulfhydryl grups (tSHG) and paraoxonase 1 activity (PON1) were determined by spectrophotometric method. Results Oxidative stress dominate in APS patients. LOOH and AOPP correlate to lipid fractions (p Conclusions Endothelial dysfunction is doubtlessly present in APS patients with oxidative imbalance as additional risk factor among other risk factors for clinical event. Anticardiolipin antibodies affect endothelial dependent vasodilatation in SAPS patients. We demonstrated synergistic effect of aCL and LOOH as risk for endothelial impairment in both PAPS and SAPS patients. References Foltyn Zadura A, Memon AA, Stojanovich L, Perricone C, Conti F, Valesini G et al (2015) Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis. J Rheumatol 42(10):1786–93. Stalc M, Poredos P, Peternel P, Tomsic M, Sebestjen M, Kveder T (2006) Endothelial function is impaired in patients with primary antiphospholipid syndrome. Thromb Res 118:455–461. Becarevic M, Stojanovich L, Ignjatovic S, Dopsaj V. The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. Clinical Rheumatology 03/2016; doi: 10.1007/s10067-016-3230–0. Ames PR, Batuca JR, Ciampa A, Iannaccone L, Delgado Alves J (2010) Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome. J Rheumatol 37:2523–2530. Acknowledgements This work was supported by research grant number 175041, and TR 32040 for 2011 - 2017, issued by the Ministry of Science of the Republic of Serbia. Disclosure of Interest None declared
Published: 2017
Full Text: View/download PDF

8. AB0515 Skin manifestations as independent predictors and the initial risk faktors for systemic antiphospholipid events

Author: N. Stanisavljevic, M Zdravkovic, Ljudmila Stojanovich, and A. Djokovic
Subjects: medicine.medical_specialty, Systemic lupus erythematosus, Acrocyanosis, business.industry, Arthritis, medicine.disease, Thrombosis, Dermatology, Rheumatology, 03 medical and health sciences, 0302 clinical medicine, Antiphospholipid syndrome, 030220 oncology & carcinogenesis, Internal medicine, medicine, medicine.symptom, business, Rheumatism, 030215 immunology, Livedo reticularis
Abstract: Background Antiphospholipid syndrome (APS) patients express skin manifestations with the presence of various levels of antiphospholipid antibodies (aPL).Several studies have shown the frequency of dermatological manifestations with APS1,2,3, including livedo reticularis, cutaneous ulcers, acrocyanosis, and other. Objectives Dermatological manifestations can be the initial clue in the diagnosis of this disease. Methods Our study includes a total of 508 APS patients; 360 were PAPS patients (283 female and 77 male, mean age 44.0±12.9 years),148 had APS associated with SLE/SAPS (133 female and 15 male,mean age 47.7±14.8 years).aPL analysis included:LA, aCL (IgG/IgM), β2GPI (IgG/IgM).In all patients, we collected data considering frequently occured skin lesions. Results Our results showed prevalence of skin manifestations in SAPS group of patinenst regading to PAPS (Table 1). Patients with skin manifestations overall had higher prevalence of thrombosis (Table 2). Conclusions Dermatological manifestations can be very often the initial symptoms of severe manifestations of APS.Our study showed that patients with secondary APS had higher prevalence of skin lesions, and that some aPL types were risk factors for thrombotic manifestations in APS patients References Toubi E, Krause I, Fraser A, Lev S, Stojanovich L, Rovensky J, et al. Livedo reticularis is a marker for predicting multi-system thrombosis in antiphospholipid syndrome. Clin Exp Rheumatol 2005;23:499–504. Weinstein S, Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am 2008;22:67–77. Asherson RA, Cervera R, Klumb E, Stojanovich L. et all.: Amputation of Digits or Limbs in Patients with Antiphospholipid Syndrome. 21 January 2008. Seminars in Arthritis and Rheumatism. 2008; 38: 124–31. Stojanovich L, Markovic O, Marisavljevic D et all. Influence of antiphospholipid antibody levels and type on thrombotic manifestations: results from the Serbian National cohort study. Lupus 2011;0: 1–8. Stojanovich L, Kontic M, Djokovic Aet all. Association between Systemic Non-criteria APS Manifestations and Antibody Type and Level: Results from the Serbian National Cohort Study. Clinical and Experimental Rheumatology, 2013,31(5):756–60. Acknowledgements This work was supported by research grant number 175041 for 2011 - 2017, issued by the Ministry of Science of the Republic of Serbia. Disclosure of Interest None declared
Published: 2017
Full Text: View/download PDF

9. Association of uric acid serum levels with hypertension and severity of sleep apnea

Author: Vesna Spasojevic-Kalimanovska, L. Memon, V. Radosavljevic, A. Zuvela, A. Ninic, M. Zdravkovic, and V. Gardijan
Subjects: medicine.medical_specialty, business.industry, Internal medicine, Biochemistry (medical), Clinical Biochemistry, medicine, Sleep apnea, General Medicine, Uric acid serum, medicine.disease, business, Biochemistry, Gastroenterology
Published: 2019
Full Text: View/download PDF

10. Perspectives: Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional Countries) project

Author: BUGIARDINI, RAFFAELE, MANFRINI, OLIVIA, L. Badimon, S. Boytsov, K. Bozidarka, I. Daullxhiu, M. Dilic, M. Dorobantu, A. Erglis, V. Gafarov, C. P. Gale, E. Goncalvesova, A. Goudev, O. Gustiene, A. Hall, I. Karpova, S. Kedev, N. Manak, D. Milicic, M. Ostojic, A. N. Parkhomenko, M. Popovici, M. Studenkan, K. Toth, D. Trninic, Z. Vasiljevic, I. Zakke, R. Zaliunas, R. Bugiardini, V. Vaccarino, O. Manfrini, B. Knezevic, M. Dorubantu, M. Ojstoic, M. Studencan, C. Gale, M. Lovric, R. Korac, D. Mandic, V. Vujovic, M. Blagojevic, J. Milekic, E. Trendafilova, D. Somleva, L. Krivokapic, G. Rajovic, O. Sahmanovic, M. Saranovic, C. Radoman, S. C. Tomic, V. Ljubic, M. Velickovic, S. Radojicic, C. Arsenescu Georfescu, S. Garbea, C. Radu, D. Olinic, P. Calin, A. Chifor, K. Babes, D. D. lonescu, E. Craiu, H. Petrescu, I. Magda, S. Luminita, I. Benedek, S. Marinescu, N. Tiberiu, G. Gheorghe, I. Malaescu, N. Trocan, D. Doina, C. Macarie, B. Putnikovic, A. Arandjelovic, N. M. Nikolic, M. Zdravkovic, J. Saric, S. Radovanovic, I. Matic, N. Srbljak, G. Davidovic, S. Simovic, S. Zivkovic, S. Petkovic Curic, R. Bugiardini, L. Badimon, O. Manfrini, S. Boytsov, K. Bozidarka, I. Daullxhiu, M. Dilic, M. Dorobantu, A. Ergli, V. Gafarov, C. P. Gale, E. Goncalvesova, A. Goudev, O. Gustiene, A. Hall, I. Karpova, S. Kedev, N. Manak, D. Milicic, M. Ostojic, A. N. Parkhomenko, M. Popovici, M. Studenkan, K. Toth, D. Trninic, Z. Vasiljevic, I. Zakke, R. Zaliuna, V. Vaccarino, B. Knezevic, M. Dorubantu, M. Ojstoic, M. Studencan, C. Gale, M. Lovric, R. Korac, D. Mandic, V. Vujovic, M. Blagojevic, J. Milekic, E. Trendafilova, D. Somleva, L. Krivokapic, G. Rajovic, O. Sahmanovic, M. Saranovic, C. Radoman, S. C. Tomic, V. Ljubic, M. Velickovic, S. Radojicic, C. Arsenescu-Georfescu, S. Garbea, C. Radu, D. Olinic, P. Calin, A. Chifor, K. Babe, D. D. lonescu, E. Craiu, H. Petrescu, I. Magda, S. Luminita, I. Benedek, S. Marinescu, N. Tiberiu, G. Gheorghe, I. Malaescu, N. Trocan, D. Doina, C. Macarie, B. Putnikovic, A. Arandjelovic, N. M. Nikolic, M. Zdravkovic, J. Saric, S. Radovanovic, I. Matic, N. Srbljak, G. Davidovic, S. Simovic, S. Zivkovic, and S. Petkovic-Curic
Subjects: Economic growth, Evidence-based practice, Cardiac catheterization and procedure, business.industry, ACUTE CORONARY SYNDROMES, International survey, Disease, Guideline, Macedonia (Republic), Disease cluster, Evidence-based secondary prevention therapy, Medicine, Cardiology and Cardiovascular Medicine, business, Soviet union, Montenegro
Abstract: During the past 10 years, the health of people in Eastern Europe and the former Soviet Union has undergone changes very different from the health patterns seen in their Western counterparts. Mortality from cardiovascular disease has been decreasing continuously in the USA and many Western European countries, but it has increased or remained unchanged in many of the states of Eastern Europe. Analysis of this phenomenon has been hindered by insufficient information. The International Registry of Acute Coronary Syndromes registry study in Transitional Countries (ISACS-TC) is both a retrospective - over a 1-year period - and prospective study which was designed in order to obtain data of patients with acute coronary syndromes (ACSs) in countries with economy in transition in Central and Eastern Europe, and herewith control and optimize internationally guideline recommended therapies in these countries. Adhesion to the project was given by 112 Collaborating Centres in 17 countries with economy in transition (Albania, Bosnia and Herzegovina, Belarius, Bulgaria, Croatia, Hungary, Kosovo, Latvia, Lithuania, Macedonia, Moldova, Montenegro, Romania, Russian Federation, Serbia, Slovakia, Slovenia, and Ukraine). A total of 47 cluster sites in 11 countries in Central and Eastern Europe are currently collaborating in ISACS-TC. The registry encourages optimal individualization of evidence-based therapies and the international patient body ensures good representation of multiple practice patterns. It may help to make an additional improvement in clinical outcomes of countries with economy in transition.
Published: 2014

11. Poster Session 2: Thursday 8 December 2011, 14:00-18:00 * Location: Poster Area

Author: X. Luo, F. Fang, J. Sun, J. Xie, A. Lee, Q. Zhang, C. Yu, O. Breithardt, S. Schiessl, M. Schmid, M. Seltmann, L. Klinghammer, C. Zeissler, M. Kuechle, W. Daniel, M. Ege, U. Guray, Y. Guray, B. Demirkan, H. Kisacik, S.-E. Kim, J.-Y. Hong, J.-H. Lee, D.-G. Park, K.-R. Han, D.-J. Oh, O. Tufekcioglu, D. C. Cozma, C. Mornos, A. Ionac, L. Petrescu, C. Tutuianu, S. I. Dragulescu, L. Guimaraes, G. Tavares, A. Rodrigues, C. Nagamatsu, C. Fischer, M. Vieira, W. Oliveira, T. Wilberg, A. Cordovil, S. Morhy, D. Muraru, M. Peluso, L. Dal Bianco, M. Beraldo, E. Solda', M. Tuveri, U. Cucchini, A. Al Mamary, L. Badano, S. Iliceto, A. Pizzuti, B. Mabritto, C. Derosa, A. Tomasello, M. Rovere, I. Parrini, M. Conte, N. Lareva, A. Govorin, R. Cooper, J. Sharif, J. D. Somauroo, J. D. Hung, V. Porcelli, R. Skevington, A. Shahzad, S. Scott, P. Lindqvist, S. Soderberg, M. Gonzalez, E. Tossavainen, M. Henein, N. Nciri, H. Saad, S. Nawas, A. Ali, A. Youssufzay, A. Safi, S. Faruk, S. Yurdakul, V. Erdemir, Y. Tayyareci, O. Yildirimturk, K. Memic, V. Aytekin, M. Gurel, S. Aytekin, M. Przewlocka-Kosmala, M. Cielecka-Prynda, A. Mysiak, W. Kosmala, S. Pescariu, D. Cozma, A. Mornos, S. Dragulescu, N. Maurea, C. G. Tocchetti, C. Coppola, C. Quintavalle, D. Rea, A. Barbieri, G. Piscopo, C. Arra, G. Condorelli, R. Iaffaioli, H. Dalen, A. Thorstensen, H. Moelmen, H. Torp, A. Stoylen, D. Augustine, C. Basagiannis, J. Suttie, P. Cox, R. Aitzaz, A. Lewandowski, M. Lazdam, C. Holloway, H. Becher, P. Leeson, S. Radovanovic, A. Djokovic, B. Todic, M. Zdravkovic, M. Zaja-Simic, S. Banicevic, D. Lisulov-Popovic, M. Krotin, J. Grapsa, D. O'regan, D. Dawson, G. Durighel, L. Howard, J. Gibbs, P. Nihoyannopoulos, C. Tulunay Kaya, M. Kilickap, H. Kurklu, N. Ozbek, C. Koca, V. Kozluca, K. Esenboga, C. Erol, B. Kusmierczyk-Droszcz, E. Kowalik, J. Niewiadomska, P. Hoffman, M. Satendra, L. Sargento, S. Lopes, S. Longo, N. Lousada, R. Palma Reis, P. Chillo, A. Rieck, J. Lwakatare, J. Lutale, E. Gerdts, S. Bonapace, G. Molon, G. Targher, A. Rossi, L. Lanzoni, G. Canali, E. Campopiano, L. Zenari, L. Bertolini, E. Barbieri, K. Hristova, L. Vladiomirova-Kitova, T. Katova, F. Nikolov, P. Nikolov, S. Georgieva, I. Simova, V. Kostova, V. A. Kuznetsov, D. V. Krinochkin, P. A. Chandraratna, Y. A. Pak, E. H. Zakharova, A. V. Plusnin, M. V. Semukhin, E. A. Gorbatenko, E. I. Yaroslavskaya, G. Bedetti, L. Gargani, M. Scalese, C. Pizzi, R. Sicari, E. Picano, M. Reali, E. Canali, S. Cimino, M. Francone, M. Mancone, R. Scardala, F. Boccalini, Y. Hiramoto, A. Frustaci, L. Agati, K. Savino, A. Lilli, E. Bordoni, C. Riccini, G. Ambrosio, D. Silva, N. Cortez-Dias, P. Carrilho-Ferreira, C. Jorge, J. Silva-Marques, A. Magalhaes, L. Santos, S. Ribeiro, F. Pinto, A. Nunes Diogo, E. Kinova, N. Zlatareva, A. Goudev, C. Bonanad, M. Lopez-Lereu, J. Monmeneu, V. Bodi, J. Sanchis, J. Nunez, F. Chaustre, A. Llacer, D. Ermacora, D. Peluso, M. Di Lazzari, P. Meimoun, F. Elmkies, T. Benali, J. Boulanger, H. Zemir, J. Clerc, A. Luycx-Bore, M. S. Velasco Del Castillo, A. Cacicedo Fernandez De Bobadilla, J. Onaindia Gandarias, M. Telleria Arrieta, G. Zugazabeitia Irazabal, O. Quintana Raczka, I. Rodriguez Sanchez, A. Romero Pereiro, E. Laraudogoitia Zaldumbide, I. Lekuona Goya, B. Bonello, E. El Louali, V. Fouilloux, I. Kammache, C. Ovaert, B. Kreitmann, A. Fraisse, R. Migliore, M. Adaniya, M. Barranco, G. Miramont, H. Tamagusuku, A. Alassar, R. Sharma, A. Marciniak, O. Valencia, N. Abdulkareem, M. Jahangiri, N. Jander, R. Kienzle, C. Gohlke-Baerwolf, H. Gohlke, F.-J. Neumann, J. Minners, S. Valbuena, F. De Torres, T. Lopez, J. J. Gomez, G. Guzman, F. Dominguez, E. Refoyo, M. Moreno, J. L. Lopez-Sendon, R. Ancona, S. Comenale Pinto, P. Caso, G. Di Salvo, S. Severino, M. Cavallaro, R. Calabro, R. Enache, R. Piazza, A. Roman-Pognuz, B. Popescu, A. Calin, C. Beladan, F. Purcarea, G. Nicolosi, C. Ginghina, O. Savu, M. Rosca, R. Jurcut, M. Serban, L. Dorobantu, E. Donal, S. Mascle, C. Thebault, D. Veillard, H. Hamonic, A. Leguerrier, H. Corbineau, B. A. Popa, M. Diena, A. Bogdan, D. Benea, G. Lanzillo, V. Casati, E. Novelli, A. Popa, G. Cerin, F. Gual Capllonch, A. Teis, J. Lopez Ayerbe, E. Ferrer, N. Vallejo, E. Gomez Denia, A. Bayes Genis, S. Spethmann, S. Schattke, G. Baldenhofer, V. Stangl, M. Laule, G. Baumann, K. Stangl, F. Knebel, C. Labata, C. Garcia Alonso, F. Gual, R. Nunez Aragon, C. Sousa, A. I. Vasile, M. Dorobantu, C. Iorgulescu, S. Bogdan, D. Constantinescu, C. Caldararu, O. Tautu, R. Vatasescu, H. Badran, M. F. Elnoamany, M. Ayad, A. Elshereef, A. Farhan, Y. Nassar, M. Yacoub, J. Costabel, G. Avegliano, P. Elissamburu, J. Thierer, F. Castro, M. Huguet, A. Frangi, R. Ronderos, C. Prinz, F. Van Buuren, L. Faber, T. Bitter, N. Bogunovic, W. Burchert, D. Horstkotte, J. D. Kasprzak, A. Smialowski, T. Rudzinski, P. Lipiec, M. Krzeminska-Pakula, K. Wierzbowska-Drabik, E. Trzos, M. Kurpesa, H. Motoki, M. Hana, T. Marwick, K. Allan, M. Vazquez-Alvarez, C. Medrano Lopez, S. Granja Da Silva, C. Marcos, A. Rodriguez-Ogando, M. Alvarez, M. Camino, M. Centeno, E. Maroto, G. Feltes Guzman, V. Serra Tomas, O. Acevedo, A. Calli, M. Barba, G. Pintos, V. Valverde, J. Zamorano Gomez, M. Marchel, J. Kochanowski, R. Piatkowski, A. Madej, K. Filipiak, I. Hausmanowa-Petrusewicz, G. Opolski, E. Malev, E. Zemtsovsky, S. Reeva, E. Timofeev, A. Pshepiy, S. Mihaila, R. Rimbas, R. Mincu, R. Dulgheru, R. Mihaila, C. Badiu, M. Cinteza, D. Vinereanu, E. Lira, D. Lebihan, C. Monaco, M. Ruiz Ortiz, D. Mesa, M. Delgado, E. Romo, M. Pena, M. Puentes, M. Santisteban, A. Lopez Granados, J. Arizon Del Prado, J. Suarez De Lezo, W.-C. Tsai, J.-Y. Shih, T.-S. Huang, Y.-W. Liu, Y.-Y. Huang, L.-M. Tsai, E. Cho, K. Choi, B. Kwon, D. Kim, S. Jang, C. Park, H. Jung, H. Jeon, H. Youn, J. Kim, A. E. Rieck, D. Cramariuc, M. Lonnebakken, B. Lund, P. Moceri, D. Doyen, P. Cerboni, E. Ferrari, W. Li, S. Goncalves, G. Vinhais De Sousa, A. G. Almeida, C. Hernandez Garcia, A. De La Rosa Hernandez, E. Arroyo Ucar, P. Jorge Perez, A. Barragan Acea, J. Lacalzada Almeida, J. Jimenez Rivera, A. Duque Garcia, I. Laynez Cerdena, O. Arhipov, A. N. Sumin, L. Campens, M. Renard, B. Trachet, P. Segers, A. De Paepe, J. De Backer, J. A. Purvis, D. Sharma, S. M. Hughes, D. Marek, D. Vindis, E. Kocianova, M. Taborsky, H. Yoon, K. Kim, Y. Ahn, M. Chung, J. Cho, J. Kang, W. Rha, O. Ozcan, D. Sezgin Ozcan, B. Candemir, M. Aras, I. Dincer, R. Atak, L. Gianturco, M. Turiel, F. Atzeni, L. Tomasoni, E. Bruschi, O. Epis, P. Sarzi-Puttini, C. Aggeli, E. Poulidakis, I. Felekos, S. Sideris, P. Dilaveris, K. Gatzoulis, C. Stefanadis, N. Roszczyk, M. Sobczak, J. Peruga, R. Krecki, J. Kasprzak, K. Ishii, T. Suyama, K. Kataoka, A. Furukawa, T. Nagai, M. Maenaka, Y. Seino, F. Musca, B. De Chiara, A. Moreo, S. Cataldo, M. Parolini, O. Parodi, T. Bombardini, F. Faita, S.-J. Park, J.-H. Kil, S.-J. Kim, S.-Y. Jang, S.-A. Chang, J.-O. Choi, S.-C. Lee, S. Park, P. Park, J. Oh, M. Cikes, V. Velagic, B. Biocina, H. Gasparovic, Z. Djuric, B. Bijnens, D. Milicic, A. Huqi, B. Klas, A. He, I. Paterson, M. Irween, J. Ezekovitz, J. Choy, Y. Chen, L. Cheng, R. Yao, H. Yao, H. Chen, C. Pan, X. Shu, B. Sobkowicz, M. Kaminska, W. Musial, R. Buechel, G. Sommer, G. Leibundgut, A. Rohner, J. Bremerich, B. Kaufmann, A. Kessel-Schaefer, M. Handke, A. Kiotsekoglou, S. Saha, R. Toole, S. Sharma, A. Gopal, S. Adhya, W. Tsang, C. Kenny, S. Kapetanakis, R. Lang, M. Monaghan, B. Smith, T. Coulter, A. Rendon, W.-S. Cheung, W. Gorissen, J. A. Ejlersen, O. May, F. J. Van Slochteren, T. Van Der Spoel, H. Hanssen, P. Doevendans, S. Chamuleau, C. De Korte, A. Tarr, S. Stoebe, T. Trache, J.-G. Kluge, A. Varga, A. Hagendorff, A. Nagy, A. Kovacs, A. Apor, B. Sax, D. Becker, B. Merkely, R. Lindquist, A. Miller, C. Reece, B. W. Eidem, W.-G. Choi, S. Kim, S. Oh, Y. Kim, R. Iacobelli, M. Chinali, M. D' Asaro, A. Toscano, A. Del Pasqua, C. Esposito, G. Seghetti, F. Parisi, G. Pongiglione, G. Rinelli, O. Omaygenc, R. Bakal, C. Dogan, K. Teber, S. Akpinar, G. Sahin, N. Ozdemir, A. Penhall, M. Joseph, F. Chong, C. De Pasquale, J. Selvanayagam, D. Leong, E. G. Nyktari, A. P. Patrianakos, C. Goudis, G. Solidakis, F. Parthenakis, P. Vardas, E. Nestaas, D. Fugelseth, A. Vitarelli, L. Capotosto, M. Bernardi, Y. Conde, F. Caranci, G. Placanica, O. Dettori, M. Vitarelli, S. De Chiara, V. De Cicco, M. Ferro', R. Calabro', S. Apostolakis, G. Chalikias, D. Tziakas, D. Stakos, A. Thomaidi, S. Konstantinides, G. Iorio, R. Rucos, G. Continanza, M. D Ascanio, L. Alessandroni, M. Saponara, M. Berry, J. Nahum, O. Zaghden, J. Monin, J. Couetil, O. Lairez, L. Macron, J. Dubois Rande, P. Gueret, P. Lim, M. Cameli, E. Giacomin, M. Lisi, S. Benincasa, F. Righini, D. Menci, M. Focardi, S. Mondillo, E. Philip, G. Gorincour, H. Bellsham-Revell, A. J. Bell, O. I. Miller, P. Beerbaum, R. Razavi, G. Greil, J. M. Simpson, S. Ann, T. Kim, J. Lee, J. Chin, P. Cabeza Lainez, V. Escolar Camas, L. Gheorghe, P. Fernandez Garcia, R. Vazquez Garcia, V. Caiulo, S. Caiulo, A. Fisicaro, F. Moramarco, G. Latini, A. Seale, J. Carvalho, H. Gardiner, M. Roughton, J. Simpson, A. Tometzki, O. Uzun, S. Webber, P. Daubeney, A. Dawood, G. Dwivedi, G. Mahadevan, D. Jiminez, R. Steeds, M. Frenneaux, C. H. Attenhofer Jost, B. Knechtle, A. Bernheim, M. Pfyffer, A. Linka, A. Faeh-Gunz, B. Seifert, G. De Pasquale, M. Zuber, A. Tomaszewski, A. Kutarski, and M. Tomaszewski
Subjects: Computer science, Plane (geometry), business.industry, Echo (computing), Left atrium, General Medicine, Biplane, medicine.anatomical_structure, Software, Left atrial, medicine, Radiology, Nuclear Medicine and imaging, Cardiology and Cardiovascular Medicine, business, Nuclear medicine
Published: 2011
Full Text: View/download PDF

12. Poster session V * Saturday 11 December 2010, 08:30-12:30

Author: Q. H. Pham, T. G. Von Lueder, S. K. Namtvedt, H. Rosjo, T. Omland, K. Steine, A. T. Timoteo, M. Mota Carmo, M. Simoes, L. M. Branco, R. C. Ferreira, R. Kato, J. Ito, T. Tahara, Y. Yokoyama, T. Ashikaga, Y. Satoh, J. O. Na, H. E. Hong, M. N. Kim, S. Y. Shin, C. U. Choi, E. J. Kim, S. W. Rha, C. G. Park, H. S. Seo, D. J. Oh, R. Ticulescu, S. Brigido, O. Vriz, L. Sparacino, B. A. Popescu, C. Ginghina, S. Carerj, G. L. Nicolosi, F. Antonini-Canterin, J. J. Onaindia Gandarias, A. Romero, E. Laraudogoitia, S. Velasco, O. Quintana, A. Cacicedo, I. Rodriguez, J. A. Alarcon, J. Gonzalez, I. Lekuona, A. Subinas, G. Abdula, L. H. Lund, R. Winter, L. Brodin, A. Sahlen, M. Masaki, Y. M. Cha, T. Yuasa, K. Dong, Y. X. Dong, S. V. Mankad, J. K. Oh, F. Vallet, B. Lequeux, C. Diakov, P. Sosner, L. Christiaens, D. Coisne, C. Kihara, K. Murata, Y. Wada, K. Uchida, T. Ueyama, S. Okuda, T. Susa, M. Matsuzaki, E. J. Cho, K. Y. Choi, B. J. Kwon, D. B. Kim, S. W. Jang, J. S. Cho, H. O. Jung, H. K. Jeon, H. J. Youn, J. H. Kim, M. Cikes, B. Bijnens, V. Velagic, T. Kopjar, D. Milicic, B. Biocina, H. Gasparovic, I. Almuntaser, A. Brown, B. Foley, N. Mulvihill, P. Crean, G. King, R. Murphy, Y. Takata, M. Taniguchi, S. Nobusada, M. Sugawara, N. Toh, K. Kusano, H. Itoh, E. Wellnhofer, C. Kriatselis, S. Nedios, J. H. Gerds-Li, E. Fleck, M. K. Poulsen, J. E. Henriksen, J. Dahl, A. Johansen, T. Haghfelt, P. F. Hoilund-Carlsen, H. Beck-Nielsen, J. E. Moller, R. Dankowski, M. Wierzchowiecki, M. Michalski, A. Nowicka, K. Szymanowska, A. Pajak, K. Poprawski, A. Szyszka, M. Kasner, D. Westermann, H. P. Schultheiss, C. Tschoepe, T. Watanabe, M. Iwai-Takano, A. Kobayashi, H. Machii, Y. Takeishi, B. P. Paelinck, P. L. Van Herck, J. M. Bosmans, C. J. Vrints, H. J. Lamb, A. Doltra, B. Vidal, E. Silva, S. Poyatos, L. Mont, A. Berruezo, A. Castel, J. M. Tolosana, J. Brugada, M. Sitges, M. Dencker, O. Bjorgell, J. Hlebowicz, Z. S. Szelenyi, G. Szenasi, M. Kiss, Z. Prohaszka, A. Patocs, I. Karadi, A. Vereckei, S. K. Saha, P. L. Anderson, S. Govind, M. Govindan, J. C. Moggridge, A. Kiotsekoglou, A. S. Gopal, B. B. Loegstrup, T. B. Christophersen, D. E. Hoefsten, J. E. Moeller, H. E. Boetker, K. Egstrup, M. Graefe, F. Q. Huang, R. S. Zhang, T. T. Le, R. S. Tan, R. Sattarzadeh Badkoubeh, A. Tavoosi, A. R. Elahian, O. Drapkina, V. I. Ivashkin, A. Fazakas, L. Pepo, O. Janosi, I. Kopitovic, A. Goncalves, P. Marcos-Alberca, C. Almeria, G. Feltes, E. Rodriguez, E. Garcia, R. Hernandez-Antolin, C. Macaya, J. Silva Cardoso, J. L. Zamorano, M. S. Navarro, M. Valentin, C. M. Banes, F. Rigo, E. Grolla, F. Tona, V. Cuaia, A. Moreo, L. Badano, A. Raviele, S. Iliceto, P. Tarzia, A. Sestito, R. Nerla, A. Di Monaco, F. Infusino, D. Matera, F. Greco, R. M. Tacchino, G. A. Lanza, F. Crea, A. Nemes, E. Balazs, K. S. Pinter, A. Egyed, M. Csanady, T. Forster, E. Holte, J. Vegsundvag, T. Hole, K. Hegbom, R. Wiseth, D. Sharif, A. Sharif-Rasslan, C. Shahla, A. Khalil, U. Rosenschein, A. Zagatina, N. Zhuravskaya, T. V. Tyurina, E. Tagliamonte, T. Cirillo, A. Coppola, U. Marinelli, C. Romano, G. Riccio, R. Citro, C. Astarita, N. Capuano, G. Quaranta, A. Desiderio, S. Frattini, P. Faggiano, V. Zilioli, E. Locantore, S. Longhi, F. Bellandi, G. Faden, M. Triggiani, L. Dei Cas, M. Dalsgaard, J. Kjaergaard, K. Iversen, C. Hassager, W. Dinh, W. N. Nickl, J. S. Smettan, T. K. Koehler, T. D. Scheffold, M. C. B. Coll Barroso, J. G. Guelker, R. F. Fueth, V. Kamperidis, S. Hadjimiltiades, G. Sianos, G. Efthimiadis, H. Karvounis, G. Parcharidis, I. H. Styliadis, M. S. Velasco Del Castillo, J. J. Onaindia, M. Telleria, H. G. Carstensen, C. Nordenberg, P. Sogaard, T. Fritz-Hansen, J. Bech, S. Galatius, J. S. Jensen, R. Mogelvang, P. E. Bartko, S. Graf, R. Rosenhek, I. G. Burwash, J. Bergler-Klein, M.-A. Clavel, H. Baumgartner, P. Pibarot, G. Mundigler, B. Kirilmaz, I. Eser, N. Tuzun, B. Komur, H. Dogan, A. Taskiran Comez, E. Ercan, M. Cusma-Piccione, C. Zito, G. Oreto, S. Piluso, S. Tripepi, L. Oreto, C. Longordo, L. Ciraci, G. Di Bella, R. Piatkowski, J. Kochanowski, P. Scislo, M. Grabowski, M. Marchel, M. Roik, D. Kosior, G. Opolski, L. Sknouril, M. Dorda, B. Holek, L. Gajdusek, J. Chovancik, M. Branny, M. Fiala, P. Szymanski, M. Lipczynska, A. Klisiewicz, P. Hoffman, N. Jander, J. Minners, G. Martin, W. Zeh, M. Allgeier, C. Gohlke-Baewolf, H. Gohlke, S. Nistri, M. C. Porciani, M. Attanasio, R. Abbate, G. F. Gensini, G. Pepe, R. F. Duncan, C. Piantadosi, A. J. Nelson, G. Wittert, B. Dundon, M. I. Worthley, S. G. Worthley, P. Jung, K. Berlinger, J. Rieber, H. Z. Sohn, P. Schneider, M. Leibig, A. Koenig, V. Klauss, L. Tomkiewicz-Pajak, J. Kolcz, M. Olszowska, M. Pieculewicz, P. Podolec, T. Przewlocki, E. Suchon, B. Sobien, P. Wilkolek, A. Ziembicka, M. Hlawaty, A. Van De Bruaene, H. Hermans, R. Buys, L. Vanhees, M. Delcroix, J.-U. Voigt, W. Budts, E. De Cillis, T. Acquaviva, D. Basile, A. S. Bortone, D. Kalimanovska-Ostric, T. Nastasovic, B. Vujisic-Tesic, I. Jovanovic, B. Milakovic, M. Dostanic, M. Stosic, A. Frogoudaki, K. Andreou, J. Parisis, E. Triantafyllidi, S. Gaitani, J. Paraskevaidis, M. Anastasiou-Nana, G. De Pasquale, A. Kuehn, K. Petzuch, J. Mueller, C. Meierhofer, S. Fratz, A. Hager, J. Hess, M. Vogt, C. H. Attenhofer Jost, J. A. Dearani, C. G. Scott, H. M. Burkhart, H. M. Connolly, A. Vitarelli, D. Battaglia, F. Caranci, V. Padella, G. Continanza, O. Dettori, L. Capotosto, M. Vitarelli, V. De Cicco, M. Cortez Morichetti, K. K. Mohanan Nair, B. Sasidaharan, A. Thajudeen, J. M. Tharakan, L. Mertens, N. Ahmad, P. K. Kantor, L. Grosse-Wortmann, M. K. Friedberg, Y. F. Bernard, M. A. Morel, V. Descotes-Genon, J. Jehl, N. Meneveau, F. Schiele, M. Kaldararova, I. Simkova, P. Tittel, J. Masura, O. Trojnarska, L. Szczepaniak, K. Mizia -Stec, A. Cieplucha, A. Bartczak, S. Grajek, A. Tykarski, Z. Gasior, D. Babovicvuksanovic, C. R. Bonnichsen, G. J. Morgan, C. Slorach, W. Hui, T. Sarkola, K. J. Lee, R. Chaturvedi, L. Benson, T. Bradley, M. E. Iancu, I. Ghiorghiu, M. Serban, I. Craciunescu, A. Hodo, J. Morgan, L. Roche, K. Lee, O. Milanesi, V. Favero, M. Padalino, R. Biffanti, A. Cerutti, N. Maschietto, E. Reffo, V. Vida, G. Stellin, O. Irtyuga, D. Gamazin, I. Voronkina, N. Tsoyi, E. Gudkova, O. Moiseeva, C. Aggeli, C. Kazazaki, I. Felekos, S. Lagoudakou, G. Roussakis, J. Skoumas, C. Pitsavos, C. Stefanadis, C. Cueff, N. Keenan, P. G. Steg, C. Cimadevilla, G. Ducrocq, A. Vahanian, D. Messika-Zeitoun, L. Petrella, A. M. Mazzola, C. V. Villani, R. G. Giancola, M. C. Ciocca, D. E. M. Di Eusanio, S. Nolan, A. Ionescu, T. R. Skaug, B. H. Amundsen, T. Hergum, H. Torp, B. O. Haugen, J. Lopez Aguilera, D. Mesa Rubio, M. Ruiz Ortiz, M. Delgado Ortega, E. Villanueva Fernandez, L. Cejudo Diaz Del Campo, F. Toledano Delgado, M. Leon Del Pino, E. Romo Pena, J. Suarez De Lezo Cruz-Conde, E. De Marco, A. Colucci, G. Comerci, F. A. Gabrielli, R. Natali, B. Garramone, M. Savino, M. Lotrionte, A. Sonaglioni, F. Loperfido, M. Zdravkovic, J. Perunicic, M. Krotin, M. Ristic, V. Vukomanovic, M. Zaja, S. Radovanovic, J. Saric, D. Zdravkovic, C. Cotrim, A. R. Almeida, R. Miranda, A. G. Almeida, E. Picano, M. Carrageta, A. D'andrea, R. Cocchia, L. Riegler, E. Golia, R. Scarafile, P. Caso, M. G. Russo, E. Bossone, R. Calabro', H. Noman, A. Adel, A. M. R. Elfaramawy, M. Abdelraouf, W. A. E. L. Elnaggar, E. Baligh, L. Sargento, D. Silva, S. Goncalves, S. Ribeiro, G. Vinhas Sousa, A. Almeida, M. Lopes, M. Rodriguez-Manero, L. Aguado Gil, P. Azcarate, P. Lloret Luna, A. Macias Gallego, S. A. R. A. Castano, M. Garcia, C. Pujol Salvador, J. Barba, P. Redondo, L. Tomasoni, S. Sitia, F. Atzeni, L. Gianturco, C. Ricci, P. Sarzi-Puttini, M. Turiel, V. De Gennaro Colonna, T. Uejima, J. Jaroch, C. Polombo, A. Hughes, D. Vinereanu, A. Evanvelista, G. Leftheriotis, A. G. Fraser, A. Lewczuk, B. Sobkowicz, A. Tomaszuk-Kazberuk, R. Sawicki, T. Hirnle, B. W. Michalski, D. Filipiak, J. D. Kasprzak, P. Lipiec, H. Dalen, O. C. Mjolstad, B. E. Klykken, T. Graven, M. Martensson, M. Olsson, L.-A. Brodin, R. Enache, E. Leiballi, A. Penhall, R. Perry, M. Altman, A. Sinhal, J. Bennetts, D. P. Chew, M. X. Joseph, L. H. Larsen, T. Kristensen, L. V. Kober, K. F. Kofoed, F. Moscoso Costa, R. Ribeiras, J. Brito, S. Boshoff, J. Neves, R. Teles, M. Canada, M. J. Andrade, R. Gouveia, A. Silva, A. Miskovic, T. P. Poerner, C. S. Stiller, B. G. Goebel, A. M. Moritz, L. Stefani, G. G. Galanti, M. Moraldo, C. Bergamini, P. A. Pabari, N. M. Dhutia, A. S. N. Malaweera, K. Willson, J. Davies, A. D. Hughes, X. Y. Xu, D. P. Francis, R. Jasaityte, B. Amundsen, D. Barbosa, D. Loeckx, G. Kiss, F. Orderud, V. Robesyn, P. Claus, J. D'hooge, T. Nao, T. Miura, K. Shams, S. Samir, R. Samir, M. El-Sayed, A. M. Anwar, Y. Nosir, A. Galal, H. Chamsi-Pasha, A. Ciobanu, R. Dulgheru, S. Bennett, A. De Luca, L. Toncelli, F. Cappelli, B. Cappelli, M. C. R. Vono, G. Galanti, Y. Zorman, M. S. Yilmazer, M. Akyildiz, T. Gurol, A. Aydin, B. Dagdeviren, and A. Kalangos
Subjects: medicine.medical_specialty, business.industry, Physical therapy, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Session (computer science), Cardiology and Cardiovascular Medicine, business
Published: 2010
Full Text: View/download PDF

13. Poster session III * Friday 10 December 2010, 08:30-12:30

Author: D. Guldbrand, O. Goetzsche, B. Eika, N. Watanabe, M. Taniguchi, T. Akagi, N. Koide, S. Sano, B. Orbovic, B. Obrenovic-Kircanski, S. Ristic, L. J. Soskic, F. Alhabshan, A. Jijeh, H. Abo Remsh, A. Alkhaldi, H. K. Najm, Z. Gasior, M. Skowerski, A. Kulach, L. Szymanski, M. Sosnowski, M. Wang, C. W. Siu, K. Lee, W. S. Yue, G. H. Yan, S. Lee, C. P. Lau, H. F. Tse, K. O'connor, M. Rosca, J. Magne, G. Romano, M. Moonen, L. A. Pierard, P. Lancellotti, M. Floria, L. De Roy, D. Blommaert, J. Jamart, F. Dormal, M. Lacrosse, C. Arsenescu Georgescu, V. Mizariene, S. Bucyte, A. Bertasiute, E. Pociute, D. Zaliaduonyte-Peksiene, K. Baronaite-Dudoniene, R. Sileikiene, J. Vaskelyte, R. Jurkevicius, M. Dencker, O. Thorsson, M. K. Karlsson, C. Linden, P. Wollmer, L. B. Andersen, O. Catalano, M. R. Perotti, E. Colombo, M. De Giorgi, M. Cattaneo, F. Cobelli, S. G. Priori, C. Ober, I. A. Iancu Adrian, P. A. Andreea Parv, C. H. Cadis Horatiu, O. M. Ober Mihai, M. Chmielecki, M. Fijalkowski, R. Galaska, W. Dubaniewicz, L. Lewicki, R. Targonski, D. Ciecwierz, W. Puchalski, A. Koprowski, A. Rynkiewicz, K. Hristova, A. La Gerche, T. Z. Katova, V. Kostova, Y. Simova, A. Kempny, G. P. Diller, S. Orwat, G. Kaleschke, G. Kerckhoff, R. Schmidt, R. M. Radke, H. Baumgartner, K. Smarz, B. Zaborska, T. Jaxa-Chamiec, P. Maciejewski, A. Budaj, A. Kiotsekoglou, S. C. Govind, V. Gadiyaram, J. C. Moggridge, M. Govindan, A. S. Gopal, S. S. Ramesh, L. A. Brodin, S. K. Saha, I. S. Ramzy, P. Lindqvist, Y. Y. Lam, A. M. Duncan, M. Y. Henein, I. S. Craciunescu, M. Serban, M. Iancu, C. Revnic, B. A. Popescu, D. Alexandru, D. Rogoz, V. Uscatescu, C. Ginghina, G. Careri, A. Di Monaco, R. Nerla, P. Tarzia, P. Lamendola, A. Sestito, G. A. Lanza, F. Crea, F. Giannini, B. Pinamonti, S. Santangelo, A. Perkan, G. Vitrella, S. Rakar, M. Merlo, E. Della Grazia, A. Salvi, G. Sinagra, P. Scislo, J. Kochanowski, R. Piatkowski, M. Roik, M. Postula, G. Opolski, J. Castillo, N. Herszkowicz, C. Ferreira, M. T. Lonnebakken, E. M. Staal, J. E. Nordrehaug, E. Gerdts, M. Przewlocka-Kosmala, A. Orda, B. Karolko, G. Bajraktari, U. Gustafsson, A. Holmgren, S. Frattini, P. Faggiano, V. Zilioli, E. Locantore, S. Longhi, F. Bellandi, G. Faden, M. Triggiani, L. Dei Cas, S. M. Seo, H. O. Jung, S. H. An, S. Y. Jung, C. S. Park, H. K. Jeon, H. J. Youn, W. B. Chung, J. H. Kim, J. S. Uhm, W. Mampuya, M. C. Brochu, D. H. Do, B. Essadiqi, P. Farand, S. Lepage, M. J. Daly, M. Monaghan, A. Hamilton, C. Lockhart, V. Kodoth, C. Maguire, A. Morton, G. Manoharan, M. S. Spence, W. Streb, K. Mitrega, J. Nowak, A. Duszanska, M. Szulik, M. Kalinowski, T. Kukulski, Z. Kalarus, F. E. Calvo Iglesias, I. Solla-Ruiz, I. Villanueva-Benito, E. Paredes-Galan, M. Bravo-Amaro, A. Iniguez-Romo, O. Yildirimturk, F. F. Helvacioglu, Y. Tayyareci, S. Yurdakul, I. C. Demiroglu, S. Aytekin, R. Enache, R. Piazza, D. Muraru, A. Roman-Pognuz, A. Calin, E. Leiballi, F. Antonini-Canterin, G. L. Nicolosi, C. Ridard, A. Bellouin, C. Thebault, M. Laurent, E. Donal, A. Sutandar, B. B. Siswanto, I. Irmalita, G. Harimurti, A. Saxena, S. Ramakrishnan, A. Roy, A. Krishnan, P. Misra, B. Bhargava, P. A. Poole-Wilson, B. B. Loegstrup, H. R. Andersen, S. H. Poulsen, K. E. Klaaborg, H. E. Egeblad, X. Gu, X. Y. Gu, Y. H. He, Z. A. Li, J. C. Han, J. Chen, N. Mansencal, E. Mitry, P. Rougier, O. Dubourg, H. Villarraga, K. Adjei-Twum, T. K. M. Cudjoe, A. Clavell, R. M. Schears, F. Cabrera Bueno, M. J. Molina Mora, J. Fernandez Pastor, A. Linde Estrella, J. L. Pena Hernandez, G. Isasti Aizpurua, F. Carrasco Chinchilla, A. Barrera Cordero, F. J. Alzueta Rodriguez, E. De Teresa Galvan, G. C. Gaetano Contegiacomo, F. P. Francesco Pollice, P. P. Paolo Pollice, M. C. Kontos, D. H. Shin, S. Y. Yoo, C. K. Lee, J. K. Jang, S. I. Jung, S. I. Song, S. I. Seo, S. S. Cheong, J. Peteiro, A. Perez-Perez, A. Bouzas-Mosquera, M. Pineiro, P. Pazos, R. Campo, A. Castro-Beiras, N. Gaibazzi, F. Rigo, D. Sartorio, C. Reverberi, S. Sitia, L. Tomasoni, L. Gianturco, L. Ghio, D. Stella, P. Greco, V. De Gennaro Colonna, M. Turiel, S. Cicala, V. Magagnin, E. Caiani, S. Kyrzopoulos, D. Tsiapras, G. Domproglou, E. Avramidou, V. Voudris, K. Wierzbowska-Drabik, P. Lipiec, L. Chrzanowski, N. Roszczyk, K. Kupczynska, J. D. Kasprzak, V. Sachpekidis, A. Bhan, S. Gianstefani, J. Reiken, M. Paul, P. Pearson, D. Harries, M. J. Monaghan, K. Dale, A. Stoylen, V. Kodali, R. Toole, P. Raju, R. A. Mcintosh, J. Silberbauer, O. Baumann, N. R. Patel, N. Sulke, U. Trivedi, J. Hyde, G. Venn, G. Lloyd, P. Wejner-Mik, K. Wierzbowska, J. A. Lowenstein, C. Caniggia, A. Garcia, M. Amor, N. Casso, D. Lowenstein Haber, C. Porley, G. Zambrana, V. Daru, M. Deljanin Ilic, S. Ilic, D. Kalimanovska Ostric, V. Stoickov, M. Zdravkovic, I. Paraskevaidis, I. Ikonomidis, J. Parissis, C. Papadopoulos, V. Stasinos, V. Bistola, M. Anastasiou-Nana, M. Gudin Uriel, J. R. Balaguer Malfagon, J. L. Perez Bosca, F. Ridocci Soriano, N. Martinez Alzamora, R. Paya Serrano, Q. Ciampi, L. Pratali, M. Della Porta, B. Petruzziello, B. Villari, E. Picano, R. Sicari, A. Rosner, D. Avenarius, S. Malm, A. Iqbal, A. Baltabaeva, G. R. Sutherland, B. Bijnens, T. Myrmel, M. Andersen, F. Gustafsson, N. H. Secher, P. Brassard, A. S. Jensen, C. Hassager, P. L. Madsen, J. E. Moller, M. Coutu, D. Greentree, D. Normandin, H. Brun, A. Dipchand, L. Koopman, C. T. Fackoury, S. Truong, C. Manlhiot, L. Mertens, M. Baroni, M. Mariani, H. K. Chabane, S. Berti, A. Ripoli, S. Storti, M. Glauber, P. A. Scopelliti, G. B. Antongiovanni, D. Personeni, A. Saino, M. Tespili, P. Jung, M. Mueller, F. Jander, H. Y. Sohn, J. Rieber, P. Schneider, V. Klauss, E. Agricola, M. Slavich, S. Stella, M. Ancona, M. Oppizzi, L. Bertoglio, G. Melissano, A. Margonato, R. Chiesa, L. Cejudo Diaz Del Campo, D. Mesa Rubio, M. Ruiz Ortiz, M. Delgado Ortega, E. Villanueva Fernandez, J. Lopez Aguilera, F. Toledano Delgado, M. Pan Alvarez-Ossorio, J. Suarez De Lezo Cruz Conde, M. Lafuente, T. Butz, A. Meissner, C. N. Lang, M. W. Prull, G. Plehn, H. J. Trappe, S. V. Nair, L. Lee, I. Mcleod, G. Whyte, J. Shrimpton, D. Hildick Smith, P. R. James, J. Slikkerveer, Y. E. A. Appelman, G. Veen, T. R. Porter, O. Kamp, P. Colonna, F. J. Ten Cate, D. Bokor, A. Daponte, M. Cocciolo, M. Bona, S. Sacchi, H. Becher, S. C. Chai, P. J. Tan, Y. S. Goh, S. H. Ong, J. Chow, L. L. Lee, P. P. Goh, K. L. Tong, R. Kakihara, C. Naruse, H. Hironaka, T. Tsuzuku, K. Ozawa, A. Tomaszuk-Kazberuk, B. Sobkowicz, J. Malyszko, J. S. Malyszko, R. Sawicki, T. Hirnle, S. Dobrzycki, M. Mysliwiec, W. J. Musial, W. Mathias, I. Kowatsch, A. L. R. Saroute, A. F. F. Osorio, J. C. N. Sbano, J. A. F. Ramires, J. M. Tsutsui, K. Sakata, H. Ito, K. Ishii, T. Sakuma, K. Iwakura, H. Yoshino, J. Yoshikawa, K. Shahgaldi, A. Lopez, B. Fernstrom, A. Sahlen, R. Winter, S. Kovalova, J. Necas, B. H. Amundsen, R. Jasaityte, G. Kiss, D. Barbosa, J. D'hooge, H. Torp, C. A. Szmigielski, J. D. Newton, K. Rajpoot, J. A. Noble, R. Kerber, L. P. Koopman, C. Slorach, N. Chahal, W. Hui, T. Sarkola, T. J. Bradley, E. T. Jaeggi, B. W. Mccrindle, A. Staron, M. Jasinski, S. Wos, P. Sengupta, D. Hayat, M. Kloeckner, J. Nahum, C. Dussault, J. L. Dubois Rande, P. Gueret, P. Lim, G. J. King, A. Brown, E. Ho, I. Amuntaser, K. Bennet, N. Mc Elhome, R. T. Murphy, R. M. Cooper, J. D. Somauroo, R. E. Shave, K. L. Williams, J. Forster, C. George, T. Bett, K. P. George, A. D'andrea, L. Riegler, R. Cocchia, E. Golia, R. Gravino, G. Salerno, R. Citro, P. I. O. Caso, E. Bossone, R. Calabro', F. Crispi, F. Figueras, J. Bartrons, E. Eixarch, F. Le Noble, A. Ahmed, E. Gratacos, Q. Shang, W. K. Yip, L. S. Tam, Q. Zhang, C. M. Li, T. Wang, C. Y. Ma, K. M. Li, C. M. Yu, T. Dahlslett, I. Helland, T. Edvardsen, H. Skulstad, L. S. Magda, M. Florescu, A. Ciobanu, R. Dulgheru, R. Mincu, D. Vinereanu, M. Luckie, S. Chacko, S. Nair, M. Mamas, R. S. Khattar, M. El-Omar, A. Kuch-Wocial, P. Pruszczyk, M. Szulc, G. Styczynski, M. Sinski, A. Kaczynska, Z. Vela, E. Haliti, V. Hyseni, R. Olloni, N. Rexhepaj, S. Elezi, J. J. Onaindia, O. Quintana, A. Cacicedo, S. Velasco, J. J. Alarcon, M. Morillas, J. R. Rumoroso, J. Zumalde, I. Lekuona, E. Laraudogoitia Zaldumbide, A. Poniku, A. Ahmeti, R. F. Duncan, J. M. Mccomb, J. Pemberton, S. W. Lord, D. Leong, C. Plummer, G. Macgowan, N. Grubb, M. Leung, A. Kenny, C. Prinz, J. U. Voigt, A. Zaidi, M. Heatley, S. Z. Abildstrom, A. Hvelplund, J. Berning, S. Govind, L. Brodin, A. Gopal, B. Castaldi, G. Di Salvo, G. Santoro, G. Gaio, M. T. Palladino, C. Iacono, G. Pacileo, M. G. Russo, R. Calabro, Y. S. Wang, L. L. Dong, X. H. Shu, C. Z. Pan, D. X. Zhou, T. Sen, O. Tufekcioglu, M. Ozdemir, A. Tuncez, B. Uygur, Z. Golbasi, H. Kisacik, L. Delfino, F. D. De Leo, L. C. Chiappa, B. Abdel Ghani, R. Schiavina, P. Salvade, A. Morganti, F. Bedogni, P. Mahia, L. Gutierrez, V. Pineda, B. Garcia, I. Otaegui, J. F. Rodriguez, M. T. Gonzalez, M. Descalzo, A. Evangelista, D. Garcia-Dorado, H. A. C. M. Bruin De- Bon, R. B. A. Van Den Brink, S. Surie, P. Bresser, J. Vleugels, H. M. Eckmann, D. A. Samson, B. J. Bouma, C. Dedobbeleer, M. Antoine, M. Remmelink, P. Unger, B. Roosens, I. Hmila, S. Hernot, S. Droogmans, G. Van Camp, T. Lahoutte, S. Muyldermans, B. Cosyns, G. Feltes, V. Serra, O. Azevedo, J. Barbado, J. Herrera, A. Rivera, J. Paniagua, V. Valverde, J. Torras, G. Arriba, T. Christodoulides, M. Ioannides, K. Simamonian, K. Yiangou, M. Myrianthefs, E. Nicolaides, M. Pandolfo, S. A. Kleijn, M. F. A. A. Aly, C. B. Terwee, A. C. Van Rossum, V. Delgado, M. Shanks, H. M. Siebelink, A. Sieders, H. Lamb, N. Ajmone Marsan, J. Westenberg, A. De Roos, J. D. Schuijf, J. J. Bax, A. M. Anwar, Y. Nosir, H. Chamsi-Pasha, H. D. Tschernich, J. Seeburger, M. Borger, C. Mukherjee, F. W. Mohr, J. Ender, K. Obase, H. Okura, R. Yamada, Y. Miyamoto, K. Saito, K. Imai, A. Hayashida, and K. Yoshida
Subjects: medicine.medical_specialty, business.industry, Physical therapy, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Session (computer science), Cardiology and Cardiovascular Medicine, business
Published: 2010
Full Text: View/download PDF

14. Malignant peripheral nerve sheath tumour in a dog presenting as a pseudo aneurysm of the left jugular vein: a case report

Author: M. Stojanovic, M. Kostov, M. Zdravkovic, M. Visnjic, D. Mihailovic, and Zaklina Mijovic
Subjects: 0301 basic medicine, General Veterinary, 040301 veterinary sciences, business.industry, 04 agricultural and veterinary sciences, Anatomy, Pseudo aneurysm, 0403 veterinary science, 03 medical and health sciences, 030104 developmental biology, Jugular vein, Medicine, Malignant peripheral nerve sheath tumour, business
Published: 2008
Full Text: View/download PDF

15. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency

Author: R. Savine, Mieke Bex, John P. Monson, M. Zdravkovic, Martin Reincke, T. Vetter, Johan Svensson, Albert Beckers, Torben Hansen, Márta Korbonits, Bengt-Åke Bengtsson, Peter H. Kann, C. Hagen, and M. M. Ilondo
Subjects: medicine.medical_specialty, Chemotherapy, business.industry, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Placebo, medicine.disease, Growth hormone deficiency, Endocrinology, Blood pressure, Oral administration, Growth hormone secretagogue, Internal medicine, Statistical significance, medicine, business, Hormone
Abstract: Summary objective Little is known of the usefulness of GH secretagogues (GHSs) in GH-deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults. design A multicentre, randomized, double-blind, and placebo-controlled study. patients Ninety-seven GHD adults were included. measurements The GH response before and after 1 week of oral treatment with NN703 (n = 83) or placebo (n = 14) was determined. The first and last dose of NN703 was 3 mg/kg, whereas the dose of NN703 was 1·5 mg/kg/day during the 6 days between the first and last doses. Furthermore, all 97 patients received 1 µg/kg GH-releasing hormone (GHRH) 3 weeks after the last dose of NN703. results Serum GH peak and area under curve (AUC) values after the first NN703 administration were greater than those after placebo administration (P < 0·05). However, after correction for the lower body mass index (BMI) in the NN703 group, this difference lost statistical significance. After 1 week of therapy, GH peak and AUC values were similar following the final doses of NN703 and placebo. Serum peak and AUC values of other anterior pituitary hormones were similar between the NN703 and placebo groups both after the first and last administration of study drug. Nine of the 83 patients (11%) responded with a serum peak GH concentration ≥ 5 µg/l after the first and/or last NN703 administration, whereas no patient responded after placebo administration. Serum IGF-I was unaffected by 1-week NN703 treatment, whereas serum IGFBP-3 was increased (P
Published: 2003
Full Text: View/download PDF

16. Isolated Serratus Anterior Paralysis: A Simple Surgical Procedure to Reestablish Scapulo-Humeral Dynamics

Author: M. Zdravkovic, D. Ukropina, M. Bumbasirevic, G. Pecotic, M. Ille, and V. Vukov
Subjects: Adult, Male, Shoulder, Inferior angle of the scapula, medicine.medical_specialty, Serratus anterior muscle, Fixation (surgical), Scapula, medicine, Paralysis, Shoulder function, Humans, Orthopedics and Sports Medicine, Range of Motion, Articular, Muscle, Skeletal, Thoracic Nerves, Arm elevation, business.industry, General Medicine, Anatomy, Middle Aged, musculoskeletal system, Nonoperative treatment, Surgery, body regions, Treatment Outcome, medicine.anatomical_structure, Surgical Procedures, Operative, Female, medicine.symptom, business
Abstract: We present an original surgical technique for the treatment of an isolated paralysis of the serratus anterior muscle. We used this technique on six patients in whom nonoperative treatment failed. We fixed the inferior angle of the scapula at approximately 35 degrees of lateral position with synthetic ribbon: not to the rib behind the inferior scapular angle but to the next lower rib, usually the eighth. Therefore the scapula was not fixed directly to the pectoral cage, but over a loop of 2-2.5 cm in length. This is the crux of the procedure, because this "loose" fixation enables lateral movement of the scapula and complete painless arm elevation without scapular winging. The follow-up period was 1-7 years (mean, 4 years and 9 months). The clinical results were "excellent" for five patients and "very good" in one patient. We recommend this procedure for its excellent restoration of shoulder function.
Published: 1996
Full Text: View/download PDF

17. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Author: M, Marre, J, Shaw, M, Brändle, W M W, Bebakar, N A, Kamaruddin, J, Strand, M, Zdravkovic, T D, Le Thi, S, Colagiuri, and A, Dayan
Subjects: Blood Glucose, Male, medicine.medical_specialty, dipeptidyl peptidase-4, Endocrinology, Diabetes and Metabolism, glucagon-like peptide-1 receptor agonist, Type 2 diabetes, thiazolidinedione, Placebo, Gastroenterology, Rosiglitazone, Endocrinology, Double-Blind Method, Glucagon-Like Peptide 1, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Aged, business.industry, Liraglutide, Body Weight, Original Articles, Middle Aged, medicine.disease, Glucagon-like peptide-1, Hypoglycemia, incretin, Albiglutide, Treatment, Glimepiride, Postprandial, Sulfonylurea Compounds, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Thiazolidinediones, business, medicine.drug, insulinotropic
Abstract: Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n ≥ 228) or placebo (n = 114) with glimepiride (2–4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± sd), age 56 ± 10 years, weight 82 ± 17 kg and glycated haemoglobin (HbA1c) 8.4 ± 1.0% at 116 sites in 21 countries were stratified based on previous oral glucose-lowering mono : combination therapies (30 : 70%) to participate in a five-arm, 26-week, double-dummy, randomized study. Results Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P
Published: 2009

18. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study

Author: Y Matsumura, L V Jacobsen, M Zdravkovic, S Kageyama, and S Irie
Subjects: Adult, Blood Glucose, Male, medicine.medical_specialty, Injections, Subcutaneous, Incretin, Pharmacology, Hypoglycemia, Placebo, Gastroenterology, Pharmacokinetics, Double-Blind Method, Japan, Glucagon-Like Peptide 1, Internal medicine, Weight Loss, medicine, Humans, Hypoglycemic Agents, Pharmacology (medical), Tissue Distribution, Dose-Response Relationship, Drug, Liraglutide, business.industry, Middle Aged, medicine.disease, Postprandial, Tolerability, Diabetes Mellitus, Type 2, Pharmacodynamics, Area Under Curve, business, medicine.drug, Half-Life
Abstract: Objectives Liraglutide is a once-daily human GLP-1 analog being developed as a Type 2 diabetes therapy. A dose-finding study in Japanese patients with Type 2 diabetes showed liraglutide to produce dose-dependent decreases in HbA(1C). Studies have also shown that, with stepped dose titration, liraglutide is well tolerated. This double-blind trial in 24 healthy Japanese men assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of once-daily subcutaneous (s.c.) liraglutide using doses exceeding those previously studied, and using the stepped titration approach. Materials and methods Subjects were randomized to three groups in each of which 6 received liraglutide, and 2 placebo for 35 consecutive days. The daily dose of liraglutide was stepped from 5 microg/kg (s.c. abdomen, morning) to 10 and then 15 microg/kg at 7-day intervals. One group remained at this dose, the others titrating further to 20 and 25 microg/kg, respectively. Subjects remained at the study site from Day 21 until the end of the trial, with standard meals served during inhouse periods. Results No safety issues, hypoglycemia, gastrointestinal or any other adverse events were observed. Liraglutide showed dose-dependent increases in the pharmacokinetic parameters of AUC0-24 h, C(max) and C(trough), while t(max), t(1/2) and V(d/F) were constant. Mean plasma glucose concentrations were similar across all treatment groups at baseline, but dose-dependent decreases in mean and postprandial plasma glucose were seen with liraglutide, although all values remained within normal ranges. There was a tendency for weight to decrease with liraglutide in comparison to placebo. Conclusions Liraglutide appears to be well tolerated at doses of up to 25 microg/kg in Japanese subjects. Despite clear pharmacodynamic effects in this euglycemic cohort, a low risk for hypoglycemia was suggested together with good gastrointestinal tolerability.
Published: 2008

19. Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-Daily Human GLP- 1 Analog, Compared With Glimepiride: All as Monotherapy In Type 2 Diabetes

Author: Robert E. Ratner, M. Zdravkovic, Robert R. Henry, H.M. Rodriquez Pattzi, Alan M. Garber, Bruce W. Bode, I. Olvera-Alvarez, P. Garcia-Hernandez, and Paula M Hale
Subjects: medicine.medical_specialty, business.industry, Liraglutide, Endocrinology, Diabetes and Metabolism, Weight change, General Medicine, Type 2 diabetes, Hypoglycemia, Placebo, medicine.disease, Gastroenterology, Glimepiride, Endocrinology, Weight loss, Internal medicine, Internal Medicine, medicine, medicine.symptom, business, Glycemic, medicine.drug
Abstract: Effect of the GLP-1 Analog Liraglutide on Glycemic Control and Weight Reduction in Patients on Metformin and Rosiglitazone: a Randomized Double-Blind PlaceboControlled Trial. B. ZINMAN*, J. GERICH, J. BUSE, A. LEWIN, S. L. SCHWARTZ, P. RASKIN, P. M. HALE, M. ZDRAVKOVIC, L. BLONDE, University of Toronto, Canada; Rochester University Medical School, NY; North Carolina University Medical School, Chapel Hill, NC; National Research Institute, Los Angeles, CA; DGD Research, San Antonio, CA; Texas University, Dallas, TX; Novo Nordisk, Princeton, NJ, USA; Bagsvaerd, Denmark; Ochsner Medical Center, New Orleans, LA, USA This 26-week randomized trial compared the efficacy and safety of two doses of liraglutide (lira; 1.2 and 1.8 mg, OD) to placebo (plb) in patients with Type 2 DM on metformin 2 g (met; 1 g, BD) and rosiglitizone 8 mg (rosi; 4 mg, BD). Subjects were previously treated with 1 or more oral antidiabetic drugs (OADs). 533 subjects were randomized (mean age 55.1±10.2 years, mean BMI 33.5±5.2 kg/m, mean HbA1c 8.3±1.0%). All patients received run-in rosi and met therapy before being randomized to lira or lira plb. Lira 1.2 mg and 1.8 mg reduced HbA1c more than placebo (ANCOVA, p
Published: 2008
Full Text: View/download PDF

20. 1119 Echocardiographic parameters influencing quality of life 5 years after myocardial revascularization

Author: Natasa Milic, M. Zaja, D. Zdravkovic, M. Ristic, D. Zamaklar-Trifunovic, Mirjana Krotin, Nikola Milinic, and M. Zdravkovic
Subjects: medicine.medical_specialty, Myocardial revascularization, Quality of life (healthcare), business.industry, Internal medicine, Cardiology, Medicine, Radiology, Nuclear Medicine and imaging, General Medicine, Cardiology and Cardiovascular Medicine, business, Coronary revascularization
Published: 2006
Full Text: View/download PDF

21. Pulse pressure and rate-pressure product during rehabilitation at low altitude in hypertensive patients

Author: R Zivkovic, M Zdravkovic, Lj Suric-Lambic, and M. Vasiljević
Subjects: Low altitude, medicine.medical_specialty, Rate pressure product, Rehabilitation, Epidemiology, business.industry, Internal medicine, medicine.medical_treatment, Cardiology, medicine, Cardiology and Cardiovascular Medicine, business, Pulse pressure
Published: 2006
Full Text: View/download PDF

22. 251 Age related changes in global and regional left ventricular diastolic function: a pulsed Doppler tissue imaging study

Author: B. Milovanovic, M. Deljanin‐Ilic, J. Andrejic, Natasa Milic, M. Zaja, R. Pokrajac, J. Tresnjak‐Korica, M. Zdravkovic, and Danijela Trifunovic-Zamaklar
Subjects: medicine.medical_specialty, Pulsed doppler, Tissue imaging, business.industry, Internal medicine, Age related, medicine, Cardiology, Diastolic function, Cardiology and Cardiovascular Medicine, business
Published: 2005
Full Text: View/download PDF

23. Is it possible to identify factors which affect the efficacy of screening for congenital malformations by ultrasonography?

Author: M. Zdravkovic, Ann Tabor, B. L. Pedersen, and A. Perslev
Subjects: Pediatrics, medicine.medical_specialty, Omphalocele, Radiological and Ultrasound Technology, medicine.diagnostic_test, Gastroschisis, Heart malformation, business.industry, Obstetrics and Gynecology, Gestational age, General Medicine, medicine.disease, Reproductive Medicine, Sonographer, medicine, Amniocentesis, Radiology, Nuclear Medicine and imaging, business, Prospective cohort study, Body mass index
Abstract: Purpose: To assess whether the efficacy of second-trimester ultrasound screening for fetal malformations is affected by patient-, staff-, team- or work environment-related factors. Methods and design: Prospective cohort study in a Danish University hospital in 1997 and 1998. Participants: A number of 7845 pregnant women who had an ultrasound screening in weeks 18–20. Ultrasound examinations were performed abdominally by eight nurses with special training in obstetrical ultrasonography. The ultrasonographers were divided into three groups according to their experience at the start of the study. Data: A record of all malformations diagnosed by ultrasound was entered into a database. Data included the name, date of birth, body mass index of the pregnant woman, date and time of the ultrasound scan, number of persons performing the scan, name of the first and last examiner, their charge and level of expertise, number of fetuses, gestational age, structural malformation diagnosed, information about amniocentesis, date of delivery, sex of the child(ren), malformation(s) diagnosed at delivery or autopsy. Follow-up of the children was done by searching their files and by a cross-check with the diagnostic registries of the two pediatric departments in the city of Copenhagen. The length of follow-up was between 12 and 36 months. The ability to detect significant malformations on ultrasound was related to: 1 factors related to the patient (body mass index, number of fetuses, gestational age at time of screening); 2 factors related to the staff (experience of sonographer); 3 factors related to the team (number of sonographers); 4 factors related to the work environment (weekday, time of day, number of scans, work monotony, number of ultrasound screenings for malformations, and work load in the ultrasound department). Results: Significant malformations were found in 106 fetuses, when followed up at least until 1 year of age, corresponding to an incidence of 1.3%. The overall detection rate was 65.1% as 69 malformations were detected and 37 were not. No case of neural tube defect, diaphragmatic hernia, gastroschisis or omphalocele was missed. Six out of seven cases of hydrocephalus were detected, while two cases of microcephaly were not. Regarding the severe heart malformations, one out of four cases of hypoplastic left heart was detected. High maternal body mass index was associated with a lower detection rate, while the presence of twins or the gestational age at the time of screening was not. There was no correlation between the sonographer's level of experience and the detection rate. Fetuses with an undetected malformation were significantly more often scanned by more than one sonographer than fetuses without malformations. There was a trend towards a lower detection rate on Thursdays, at mid-day, when most of the staff was at work, and when the number of malformation screenings exceeded 20 per day. Conclusions: In our center, 65% of significant malformations were diagnosed, a detection rate comparable to other centers, especially since we followed the children until the age of 1 year. The detection rate of fetal heart malformations was however, low, and therefore a course with special focus on this organ was offered to the sonographers. Our study demonstrates that among the patient-related factors high maternal body mass index was the only factor associated with a lower detection rate. Among the team-related factors, malformed fetuses were significantly more often examined by two sonographers than fetuses without congenital malformations. As to the factors related to the work environment, scans performed just before lunchtime or on days when most sonographers were at work seemed to have a lower detection rate. In order to minimize error, the following changes have been made: Appointments for screening were reorganized so they are not scheduled around mid-day. A morning- and a lunch-break without any planned examinations have been scheduled in order to allow all the staff to be together at some time during the day. When an experienced sonographer requests a second opinion, a doctor should give this. The new organization will be followed up in order to secure that the reorganization has not created new organizational mistakes.
Published: 2001
Full Text: View/download PDF

24. Role of ciprofibrate in treatment of hyperlipoproteinemia and other risk factors important for atherothrombogenic chronic vascular complications

Author: Lj Todorovic, R Dragojevic, M Zdravkovic, M Kocijancic, Lj Bajovic, P.B Djordjevic, R. Kocic, and S Antic
Subjects: medicine.medical_specialty, Endocrinology, business.industry, Endocrinology, Diabetes and Metabolism, Diabetes mellitus, Internal medicine, Internal Medicine, Medicine, General Medicine, Ciprofibrate, business, medicine.disease, medicine.drug
Published: 2000
Full Text: View/download PDF

25. P.1.123 Combination of amitriptyline and fluvoxamine with lithium-carbonate in the treatment of major depressive disorder

Author: B. Miljković, M. Pokrajac, M. Zdravkovic, and I. Timotijević
Subjects: Pharmacology, business.industry, Lithium carbonate, Fluvoxamine, medicine.disease, Psychiatry and Mental health, chemistry.chemical_compound, Neurology, chemistry, Endogenous depression, Medicine, Major depressive disorder, Pharmacology (medical), Amitriptyline, Neurology (clinical), business, Biological Psychiatry, medicine.drug
Published: 1997
Full Text: View/download PDF

26. Comparative study of mono and combined therapy of major depression

Author: I. Timotijević, B. Miljković, M. Pokrajac, and M. Zdravkovic
Subjects: medicine.medical_specialty, business.industry, Internal medicine, medicine, Combined therapy, business, Biological Psychiatry, Depression (differential diagnoses)
Published: 1997
Full Text: View/download PDF

27. Age of onset in MD psychosis index patients families: Genetic-epidemiological findings

Author: I. Timotijević, M. Zdravkovic, O. Marinković, and M. Nikolić
Subjects: medicine.medical_specialty, Psychosis, Index (economics), business.industry, Epidemiology, medicine, Age of onset, Psychiatry, business, medicine.disease, Biological Psychiatry
Published: 1997
Full Text: View/download PDF

28. Clozapine Pharmaco-Epidemiologic Monitoring Model

Author: O. Marinković, M. Stojanovic, M. Nikolić, I. Timotijević, and M. Zdravkovic
Subjects: Psychiatry and Mental health, medicine.medical_specialty, business.industry, medicine, Intensive care medicine, business, Clozapine, medicine.drug
Published: 1997
Full Text: View/download PDF

29. Efficacy of combined lithium/TCAs and Lithium/SSRIs therapy in major depressive disorder

Author: B. Miljković, M. Pokrajac, I. Timotijević, and M. Zdravkovic
Subjects: Pharmacology, medicine.medical_specialty, Lithium (medication), business.industry, medicine.disease, Psychiatry and Mental health, Neurology, medicine, Major depressive disorder, Pharmacology (medical), Neurology (clinical), Psychiatry, business, Biological Psychiatry, medicine.drug
Published: 1996
Full Text: View/download PDF

30. Efficacy and tolerability of mono and combined fiuvoxamine/lithium therapy in major depressive disorder

Author: M. Zdravkovic, B. Miljković, M. Pokrajac, and I. Timotijević
Subjects: Pharmacology, Oncology, Psychiatry and Mental health, medicine.medical_specialty, Tolerability, business.industry, Lithium therapy, Internal medicine, medicine, Major depressive disorder, business, medicine.disease
Published: 1995
Full Text: View/download PDF

31. Ouabain arrhythmogenicity in hypertrophied right and left ventricle of the rat

Author: V. Veljković, Dinko Susic, M. Zdravkovic, and Dušan Kentera
Subjects: Male, Cardiac Complexes, Premature, medicine.medical_specialty, Physiology, Heart Ventricles, Hypertension, Pulmonary, Cardiomegaly, Left ventricular hypertrophy, Ventricular tachycardia, Ouabain, Muscle hypertrophy, Ventricular hypertrophy, Right ventricular hypertrophy, Rats, Inbred SHR, Tachycardia, Physiology (medical), Internal medicine, medicine, Animals, cardiovascular diseases, business.industry, medicine.disease, Pulmonary hypertension, Rats, medicine.anatomical_structure, Endocrinology, Ventricle, cardiovascular system, Cardiology, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: Susceptibility to the arrhythmogenic action of ouabain was tested in rats with right ventricular hypertrophy, due to experimental chronic hypoxic pulmonary hypertension, and in spontaneously hypertensive (SH) rats with left ventricular hypertrophy. As parameters of arrhythmogenicity the time-duration of infusion of a solution of ouabain (1 g/100 ml), at a rate of 0.7 mg/kg per minute, was measured until the appearance on the ECG of the first premature ventricular contraction, ventricular tachycardia and cardiac arrest. All three effects of digitalis toxicity (premature ventricular contraction, ventricular tachycardia and cardiac arrest) appeared significantly earlier both in rats with right ventricular hypertrophy, due to chronic experimental hypoxic pulmonary hypertension, and in SH rats with hypertrophy of the left ventricle, as compared to the infusion time of the same solution of ouabain needed to elicit the mentioned toxic effects in control rats without ventricular hypertrophy.
Published: 1987
Full Text: View/download PDF

32. Hypotensive effect of heparin on experimental chronic pulmonary hypertension in rats

Author: Dušan Kentera, Dinko Susic, and M. Zdravkovic
Subjects: Pulmonary Circulation, Physiology, medicine.drug_class, Hypertension, Pulmonary, Blood Pressure, Right ventricular hypertrophy, Physiology (medical), medicine.artery, Medicine, Animals, Pulmonary Wedge Pressure, business.industry, Heparin, Anticoagulant, Rats, Inbred Strains, Hypoxia (medical), medicine.disease, Pulmonary hypertension, Rats, medicine.anatomical_structure, Blood pressure, Ventricle, Anesthesia, Pulmonary artery, Female, Vascular Resistance, medicine.symptom, Cardiology and Cardiovascular Medicine, business, medicine.drug
Abstract: Daily heparin injections (300 mg s.c.) during four weeks of hypoxic exposure resulted in a smaller rise in pulmonary artery pressure as compared with otherwise nontreated rats exposed to the same regimen of hypoxia. Heparin treatment did not significantly affect the systemic arterial pressure of the hypoxic rats. In spite of the different pressure load of the right ventricle after hypoxia in treated and control rats, there was no difference in parameters indicative of the degree of right ventricular hypertrophy between these two groups of hypoxic rats. This finding suggests that the difference in pressure load between the two groups of hypoxic rats occurred late in the course of hypoxic exposure.
Published: 1985

33. Management of heart failure complicating acute coronary syndromes in Montenegro and Serbia

Author: Sonja Radojicic, Gordana Radakovic, Gordana Rajovic, Milosavljevic Jelica, Vujica Ljubic, Irene Martelli, Lea Riger, Colovic Radoman, Djindjic Ljubica, Dimitrije Jovanovic, Ratko Lasica, D. Rajic, Akos Koller, Nevena Bankovic-Milenkovic, Ljiljana Krivokapic, Milan Velickovic, Lina Badimon, Šahmanović Omer, Mirko Saranovic, Beatrice Ricci, Zorana Vasiljevic, Slavica Cvijovic Tomic, Ljilja Music, Marija Zdravkovic, Raffaele Bugiardini, Olivia Manfrini, Sinisa Zivkovic, Božidarka Knežević, B. Knezevic, Z. Vasiljevic, L. Music, L. Krivokapic, V. Ljubic, S. C. Tomic, S. Omer, S. Radojicic, C. Radoman, G. Rajovic, L. Riger, M. Saranovic, M. Velickovic, D. Rajic, S. Zivkovic, R. Lasica, N. Bankovic-Milenkovic, D. Ljubica, D. Jovanovic, M. Jelica, G. Radakovic, M. Zdravkovic, B. Ricci, O. Manfrini, I. Martelli, A. Koller, L. Badimon, and R. Bugiardini
Subjects: Acute coronary syndrome, medicine.medical_specialty, business.industry, medicine.medical_treatment, Mortality rate, ACUTE CORONARY SYNDROMES, Management of heart failure, Percutaneous coronary intervention, Heart failure, Odds ratio, medicine.disease, Surgery, Montenegro, Internal medicine, medicine, Serbia, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, Killip class
Abstract: It is essential that context-appropriate health research and health interventions take place in countries with economy in transition. The aims of this study were to describe the clinical characteristics, management, and in-hospital outcomes of acute coronary syndrome (ACS) patients with heart failure (HF) in Montenegro and Serbia. The data of this study are a framework of the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC; [NCT01218776][1]), a multi-national and multicentre registry of patients hospitalized with ACS in the European countries that emerged from the Socialist era. The present analysis focused on participants admitted to 15 hospitals in Montenegro and Serbia with a diagnosis of ACS during the period between October 2012 and August 2013. Among 1115 patients, 94 (8.4%) had an admission diagnosis of HF (Killip Class II or III). Heart failure patients were significantly older ( P < 0.001). Heart failure was more frequently associated with hypertension. When compared with patients presenting without HF (Killip Class I), those with HF had lower rates of reperfusion therapy either by percutaneous coronary intervention (47.9 vs. 60.7%, P = 0.015) or by fibrinolysis (2.1 vs. 11.8%, P = 0.004). In multivariate logistic regression analysis, older age, prior coronary artery bypass graft, and ST-segment elevation myocardial infarction were the relevant predictor of HF at admission. Heart failure on admission was associated with a marked increase in mortality rates during hospitalization (13.8 vs. 3.7%, P < 0.001). After adjustment for differences in clinical characteristics, HF was still associated with higher mortality (odds ratio 2.88, 95% confidence interval 1.22–6.79, P = 0.016). Heart failure is observed in nearly 9% of patients with ACS in Serbia and Montenegro and is also associated with a significant increase in in-hospital mortality. More aggressive treatment of these patients is warranted to improve prognosis. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01218776&atom=%2Fehjsupp%2F16%2Fsuppl_A%2FA61.atom
Published: 2014

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources

Refine your results

33 results on '"M Zdravkovic"'

1. Increased gene expression of resistin and CD36 in peripheral blood mononuclear cells is associated with hypercholesterolemia in patients with obstructive sleep apnea

2. Management of dyslipidaemia in patients with coronary heart disease : results from the ESC-EORP EUROASPIRE V survey in 27 countries

3. AB1059 A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ANAKINRA IN PATIENTS WITH STILL´S DISEASE

4. AB0595 Antiphospholipid syndrome (HUGHES SYNDROME) is a disease with protean faces: multidisciplinary approaches on serbian cohort of aps patients

5. Romantic Love as a Threat to Social Stability in Shakespeare’s 'Romeo and Juliet' and Anouilh’s 'Romeo and Jeanette'

6. EARLY ELECTROCARDIOGRAM CHANGES IN HIGHLY TRAINED PREADOLESCENT FOOTBALL PLAYERS

7. FRI0689 Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome (APS) patients

8. AB0515 Skin manifestations as independent predictors and the initial risk faktors for systemic antiphospholipid events

9. Association of uric acid serum levels with hypertension and severity of sleep apnea

10. Perspectives: Rationale and design of the ISACS-TC (International Survey of Acute Coronary Syndromes in Transitional Countries) project

11. Poster Session 2: Thursday 8 December 2011, 14:00-18:00 * Location: Poster Area

12. Poster session V * Saturday 11 December 2010, 08:30-12:30

13. Poster session III * Friday 10 December 2010, 08:30-12:30

14. Malignant peripheral nerve sheath tumour in a dog presenting as a pseudo aneurysm of the left jugular vein: a case report

15. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency

16. Isolated Serratus Anterior Paralysis: A Simple Surgical Procedure to Reestablish Scapulo-Humeral Dynamics

17. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

18. Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study

19. Significantly Better Glycemic Control and Weight Reduction with Liraglutide, a Once-Daily Human GLP- 1 Analog, Compared With Glimepiride: All as Monotherapy In Type 2 Diabetes

20. 1119 Echocardiographic parameters influencing quality of life 5 years after myocardial revascularization

21. Pulse pressure and rate-pressure product during rehabilitation at low altitude in hypertensive patients

22. 251 Age related changes in global and regional left ventricular diastolic function: a pulsed Doppler tissue imaging study

23. Is it possible to identify factors which affect the efficacy of screening for congenital malformations by ultrasonography?

24. Role of ciprofibrate in treatment of hyperlipoproteinemia and other risk factors important for atherothrombogenic chronic vascular complications

25. P.1.123 Combination of amitriptyline and fluvoxamine with lithium-carbonate in the treatment of major depressive disorder

26. Comparative study of mono and combined therapy of major depression

27. Age of onset in MD psychosis index patients families: Genetic-epidemiological findings

28. Clozapine Pharmaco-Epidemiologic Monitoring Model

29. Efficacy of combined lithium/TCAs and Lithium/SSRIs therapy in major depressive disorder

30. Efficacy and tolerability of mono and combined fiuvoxamine/lithium therapy in major depressive disorder

31. Ouabain arrhythmogenicity in hypertrophied right and left ventricle of the rat

32. Hypotensive effect of heparin on experimental chronic pulmonary hypertension in rats

33. Management of heart failure complicating acute coronary syndromes in Montenegro and Serbia

Catalog

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

33 results on '"M Zdravkovic"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources